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Abstract 
CCL3LI and CCL4LI are chemokine genes, located on chromosome 
17q12. They are copy number variable genes which share 95% 
sequence identity with their non-copy number variable paralogues 
CCL3 and CCL4. The copy number of these genes varies between 
populations and has been reported to be associated with phenotypes 
such as susceptibility to HIV infection, hepatitis C virus infection, 
Kawasaki disease and SLE. 
The aim of this study is to understand the evolutionary history of 
variation at the CCL3L1/CCL4LI cluster. To accomplish this goal, 
several approaches including typing microsatellites, single nucleotide 
polymorphisms (SNPs) and CCL3L 1/CCL4L 1 sequence haplotypes 
were used to investigate the association with CCL3L 1 and CCL4L 1 
copy number. However, the results showed that there is no strong 
association between a single-copy marker and CCL3L 1 and CCL4LI 
copy number, but there is evidence of recombination. Therefore, this 
may suggest that CCL3L 1/CCL4L 1 is a complex region and one 
plausible hypothesis is that there is a high rate of recombination in this 
region. This study of the evolution of CCL3L 1/CCL4L 1 haplotypes 
showed that a major one-copy CCL3L 1/CCL4L I haplotype (about 70% 
haplotype frequency) identified in humans, represents the ancestral 
state, as inferred from comparison with chimpanzee. 
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Chapter 1: Introduction 
1.1 Genetic variation 
The success of the human genome project (International Human 
Genome Sequencing Consortium 2001; Venter et at 2001) and the 
revolution in biomolecular technology has had a significant role in the 
discovery of human genes and human genetic diversity. Genetic 
variation seems to contribute to many complex human diseases such 
as bipolar disorder, Crohn's disease, type 1 and 2 diabetes, coronary 
artery disease, and rheumatoid arthritis (The Wellcome Trust Case 
Control Consortium 2007,2010). Interestingly, recent studies have 
revealed that genetic variation in the CCR5 gene, which encodes a 
protein co-receptor for the entry of human immunodeficiency virus into 
human immune cells, and the CCL3LI gene, which encodes a 
chemokine, might be involved in protection against HIV/AIDS 
(Gonzalez et al. 2005). These proteins function by decreasing HIV 
infection through their effects on both cell mediated immunity and 
(other) viral entry-independent mechanisms (Dolan et al. 2007). 
Consequently, studying genetic variations that predispose or increase 
risk of these common diseases might lead to the development of new 
interventions that could have an enormous effect on medical therapy 
and benefit to public health. 
I 
Genetic variation can be present in many forms such as SNP, 
insertion/deletion variant (InDel), microsatellite, minisatellite and 
variable numbers of tandem repeats, multisite variant, copy number 
variation (CNV), inversion, translocation and unbalanced 
rearrangements (Feuk et at 2006). However, the forms that have 
interested researchers most in recent years are microsatellites, single 
nucleotide polymorphisms (SNPs) and copy number variations (CNVs). 
Those due to SNPs are the prevalent form of genetic variation and 
contribute to much normal phenotypic variation (The International SNP 
Map Working Group 2001; The International HapMap Consortium 
2005,2007; The International HapMap 3 Consortium 2010). After 
lafrate et at (2004) and Sebat et al. (2004) had reported the 
widespread presence of copy number variation in normal individuals, 
several reports showed association between copy number variation 
and common disorders (reviewed in Estivill and Armengol (2007) and 
Zhang et at (2009)). Although it seems microsatellites are currently 
less popular than SNPs and CNVs, using combined markers may 
provide more advantage than using either marker alone, such as 
increasing detail of linkage disequilibrium (LD) (Beckmann et al. 2007; 
Payseur et al. 2008). 
1.1.1 Single nucleotide polymorphisms (SNPs) 
Single nucleotide polymorphisms (SNPs) are genetic variations that 
occur when a single nucleotide in the genome sequence is altered, and 
the variant is found in more than 1% of the population (Brookes 1999). 
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They make up about 90% of known sequence variants in humans and 
are the most abundant type of genetic variation (Collins et al. 1998). At 
present, the International HapMap project has genotyped common and 
rare SNPs and reported the data for public use at 
http: //www. hapmal2. o[g (more detail is provided in section 1.2). In 
addition, in the near future, SNP information will be even more 
comprehensive on data release from the 1000 genomes project 
(http: //www. 1000genomes. orq/). This is the ongoing project with the 
aim of providing a public resource of human genetic variation using 
sequencing data from 2500 samples in 25 populations from around the 
world. Information will be included for SNPs and structural variants 
which have frequencies Z 1% in the population studied. All SNPs 
validated by experimental methods from both projects are also 
recorded in the SNP database at http: //www. ncbi. nlm. nih-oov/snp/. 
Generally, SNPs have been used as genetic markers in case-control 
studies to find genetic associations with diseases or traits. In these 
studies large-scale SNP genotyping is performed in a patient group 
and a healthy-matched control population, and their genotypes will be 
compared to look for significant differences. Then, the relationship 
between a specific genotype and a phenotype will be identified further 
for susceptibility genes that are associated with a disease (Kim and 
Misra 2007). Some examples of association between SNP alleles and 
diseases are given in section 4.2.1. 
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1.1.2 Copy number variations (CNVs) 
Recent discoveries have revealed that large segments of DNA (>100 
kb) can vary in copy-number (lafrate et at 2004; Sebat et at 2004). For 
example, genes that were thought to always occur in two copies per 
diploid genome have now been found to sometimes be present in one, 
three, or more than three copies (Figure 1.1). 
ABC Genes from reference genome 
AC Deletion of gene B 
IIAI1BIIB1! dl 
Duplication of gene B 
Figure 1.1: Copy number variation in the human genome. 
Copy number variations (CNVs) are defined as a segment of DNA that 
is Z 1kb and shows variable copy number compared to a reference 
genome, including insertions, deletions and duplications (Feuk at al. 
2006). 
To date (Nov 02,2010), it is estimated that there are 66,741 CNVs in 
the human genome (http: //proiects. tcag. ca/variation/). Recently, 
several studies have reported that CNVs are associated with 
Mendelian diseases such as mental retardation and alpha/beta 
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thalassemia, and complex/common disorders such as HIV 
susceptibility, systemic autoimmune disease and schizophrenia 
(reviewed in Zhang et al. 2009). 
However, although many studies of the association between CNVs and 
diseases have been published, and the availability of several 
techniques that can be used to genotype CNVs, such as array 
comparative genomic hybridization (arrayCGH), quantitative PCR 
(qPCR), fluorescent in situ hybridization (FISH) and next generation 
sequencing (NGS), a robust measurement of CNVs is still required 
because different techniques can provide different copy number in a 
CNV assessment and each technique has its own limitations for CNV 
genotyping (Alkan et at 2011). 
1.1.3 Microsatellites 
Microsatellites, also known as short tandem repeats (STRs) and simple 
sequence repeats (SSRs) are short DNA sequences which contain 
tandem repeat structures of 1-4 motifs. For example, "AAAAAAA" 
which is referred to as (A)7 and "GTGTGTGTGTGT" which is referred 
to as (GT)6 or G(TG)5T. Terms like mono-, di-, tri or tetranucleotide are 
often used, and these are the main types of microsatellite. However, 
the repeats of five (penta-) or six (hexa-) nucleotides are also classified 
as microsatellites (Ellegren 2004). 
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Microsatellites are abundantly distributed across genomes both in 
coding and non-coding DNA regions; they are estimated to constitute 
3% of the human genome (Ellegren 2004). Microsatellites are also 
highly variable in the sizes of their alleles. They are also found to vary 
extensively in between African, Asian and European populations (Jorde 
et al. 1997). 
Microsatellites are ubiquitous in the genome and show a high degree of 
polymorphism (informativeness). Moreover, they are convenient to 
detect using the polymerase chain reaction (PCR). As a result, 
microsatellites are popular markers for use in linkage mapping to 
identify susceptibility loci involved in human diseases. The diseases 
that microsatellites cause directly include Huntington's disease, fragile 
X syndrome, and myotonic dystrophy (reviewed in Cummings and 
Zoghbi (2000)). Microsatellite analysis is also one approach for 
studying complex diseases such as cancer (Ginzinger et at 2000; 
Popat et at 2005) and schizophrenia (Virgos at at 2001; Bailer at at 
2002). In addition to their applications in genome mapping, these 
markers have been applied in a variety of fields such as personal 
identification (Thomson et at 1999; Staiti at at 2004), population 
genetic analysis and the construction of human evolutionary trees 
(Zhivotovsky et at 2003). 
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1.2 The International HapMap Project 
1.2.1 Background and concept 
To date, there are approximately 19.7 million SNPs currently recorded 
in the human genome 
(http: //www. ncbi. nlm nihyo v/Droiects/SNP/snp summary cgi), meaning 
if all SNPs were tested, it would be extremely expensive, laborious and 
time consuming. 
Nevertheless, SNPs are generally found close together in blocks, 
called haplotype blocks (Gabriel et al. 2002) and the haplotypes in an 
individual DNA can be identified by tag-SNPs (Johnson et a/. 2001). As 
a result, tag-SNPs are exploited to determine the collection of 
haplotypes present in each subject instead of examination all SNPs in 
an individual DNA. An example of the relationship between SNPs, 
haplotypes and tag-SNPs is shown in Figure 1.2. 
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a) SNPs SNP SNP SNP SNP SNP SNP 
Chromosome I ACTGGTCATTATCA 
......... 
GGCACACGAGGACAT 
Chromosome 2 ACTCGTCGTTAACA 
....... 
GGCGCACAAGGTCAT 
b) Haplotypes Haplotype block 1 Haplotype block 2 
Haplotype 1GATAGA 
Haplotype 2CGAGAT 
11 
c) Tag-SNPs A 
G 
Figure 1.2: An example of SNPs, haplotypes and tag-SNPs. 
a. SNPs: Most of the DNA sequences between two chromosomes are 
identical, but there are variant bases that have arisen in three loci 
between these two chromosomes. 
b. Haplotypes: A set of SNPs on the chromosome that are transmitted 
together, and these SNPs can be found together in a block, called a 
haplotype block. 
c. Tag-SNPs: haplotype blocks can be tagged by genotyping a SNP 
located in the blocks. 
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1.2.2 The International HapMap Project 
The International HapMap Project was encouraged by two studies, 
Reich et al. (2001) and Gabriel et al. (2002), which showed that 
haplotypes across populations are shared, and only a few common 
haplotypes are observed. So, in theory it should be possible to use 
these haplotypes as a powerful tool to discover disease genes. 
The International HapMap Project was founded by the collaboration 
among organizations in Japan, the United Kingdom, Canada, China, 
the United States and Nigeria. The objective was to determine the 
patterns of common human genetic variation, by characterizing 
sequence variants, their frequencies, and correlations between them. 
This has been a useful research tool for researchers to identify genetic 
factors that contribute to health, disease and drug response in human 
(The International HapMap Consortium 2003). 
The International HapMap Project started with 269 samples from four 
populations: (1) 90 individuals (30 parent-offspring trios) from the 
Yoruba in Ibadan, Nigeria (Abbreviation YRI); (2) 90 individuals (30 
trios) from Utah, USA, selected from the Centre d'Etude du 
Polymorphisme Humain collection (abbreviation CEU); (3) 45 Han 
Chinese in Beijing, China (Abbreviation CHB); (4) 44 Japanese in 
Tokyo, Japan (Abbreviation JPT). The sampling of human populations 
was selected on the basis that these populations will represent most 
genetic variation found in all populations throughout the world (based 
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on their allele frequency distributions and similarity in haplotype 
patterns in the pilot studies) (The International HapMap Consortium 
2003). The project was divided into two phases: Phase I and Phase II. 
However, the data from HapMap Phase I and II have limitations; for 
example, they do not provide information on rare variants and 
structural variants (Manolio and Collins 2009). As a result, The 
International HapMap Project continued to expand the HapMap Phase 
I and II data, calling this expansion HapMap 3, with the aim of providing 
information on rarer variants and copy number polymorphisms in 
populations with a wide range of ancestry. These data were just 
published in 2010. 
1.2.2.1 The Phase I HapMap 
Phase I of the International HapMap Project consisted of 2 sections: 
first, to genotype at least one common SNP with a minor allele 
frequency of 0.05 or greater every 5kb across the human genome in 
each of 269 DNA samples from four populations, including YRI, CEU, 
CHB and JPT; and second, to compare genotyping data with ten 
selected 500-kb regions from the ENCODE (Encyclopedia of DNA 
Elements) project (http: //www. genome. gov/10005107). 
The data from phase I HapMap showed that it contained 1,007,329 
SNPs, and 17,944 SNPs discovered in the ENCODE regions (one per 
279 bp). The International HapMap project also identified 
recombination hotspots and the block-like structure of linkage 
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disequilibrium. Moreover, analysis of the phase I map showed that 
between 260,000 and 474,000 tag-SNPs are required to capture all 
common SNPs in the phase I data set (The International HapMap 
Consortium 2005). 
1.2.2.2 The Phase II HapMap 
A further 2.1 million SNPs were genotyped on the same individuals that 
were used in phase I. The data showed that there are 1.14 genotyped 
polymorphic SNPs per kilobase, and 0.5-1.09 million SNPs are 
required to capture all common Phase II SNPs with r2 z 0.8 (The 
International HapMap Consortium 2007). r2 is one of the measures of 
linkage disequilibrium (LD). It is the correlation coefficient of alleles at 
the two loci. It will range between 0 and 1; r2 =1 is perfect LD. This 
indicates that there is no evidence of recombination between the pair of 
SNPs, and also shows that the SNPs have the same allele frequency 
(Ardlie et al. 2002). 
1.2.2.3 HapMap 3 
HapMap 3 is an expansion of the HapMap Phase I and II resources. It 
combines data sets of common and rare alleles, including both SNPs 
and copy number polymorphisms (CNPs) by genotyping 1.6 million 
SNPs in 1,184 DNA samples from 11 populations and sequencing ten 
100-kb regions in 692 of these DNA samples. The samples include the 
same four populations from HapMap Phase I and II and additional 
samples from seven populations: (1) Luhya in Webuye, Kenya 
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(Abbreviation LWK); (2) Maasai in Kinyawa, Kenya (Abbreviation 
MKK); (3) Tuscans in Italy (Abbreviation TSI); (4) Gujarati Indian in 
Houston, Texas, USA (Abbreviation GIH); (5) Denver (Colorado) 
metropolitan Chinese community (Abbreviation CHD); (6) people of 
Mexican origin in Los Angeles, California, USA (Abbreviation MXL); (7) 
people with African ancestry in the southwestern United States 
(Abbreviation ASW). In summary, HapMap 3 found that rare alleles are 
less shared across populations of study, even in the closely related 
populations (The International HapMap 3 Consortium 2010). 
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1.3 Linkage disequilibrium (LD) concept and haplotype blocks 
1.3.1 The patterns and factors that influence linkage 
disequilibrium 
Linkage disequilibrium (LD) is the association of alleles at different loci 
being found together more often than expected by chance (Figure 1.3). 
Region 1 +--- 100kb Region 2 
SNP A SNP B SNP C SNP X SNP Y SNP Z 
A IGC A C A 
GT A A 
A GT A T 
T C, T T T 
T CC 
d 
A 
A GC A G T 
A GT A A 
T CC i T G A 
A _ GC A C T 
T CT T G T 
Figure 1.3: An example of linkage disequilibrium. 
SNP A at region 1 has a perfect LD with its neighbour, SNP B, and with 
SNP X at region 2, although they are located a distance of 100kb apart. 
However, LD will not be maintained over indefinitely long time periods. 
The pattern of LD will gradually break down through recombination, 
mostly at hot spots which are found about every 1 in 50kb across the 
human genome (Jeffreys et al. 2001; Myers et al. 2005). 
Recombination hot spots will thus separate SNPs into blocks, called 
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haplotype blocks (Figure 1.4) (Daly et al. 2001; Reich et al. 2001; 
Gabriel et al. 2002). Although LD decays rapidly between the blocks, it 
will be still maintained within the block. Johnson et a/. (2001) 
demonstrated that using LD mapping, which is a method to determine 
the non-random association of alleles at two more different loci on a 
chromosome, can reduce significantly the number of SNPs which are 
required for genotyping; in their study, common haplotypes in 9 genes 
of European populations could be identified with 34 SNPs from a total 
of 122 SNPs. 
Based on the characteristics of LD, therefore, to save the cost and time 
of genotyping all SNPs in the block without the loss of SNP information, 
genotyping a set of selected SNPs (i. e. tag-SNPs) in the block should 
provide sufficient SNP information to use to identify all haplotypes in 
the block precisely. A further example is shown in Figure 1.4. 
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Figure 1.4: Examples of haplotype blocks, revealed by Haploview, in the CEPH- 
HapMap population at Chr. 17: 31,889,664-31,936,690. 
a) The haplotype blocks are shown outlined, The colours indicate LD in terms of D' 
and their statistically significant evidence (log odds; LOD) between pairs of SNPs. In 
brief, the white colour indicates low LD (D' <1) with low statistical significance (LOD 
<2), the blue colour shows perfect LD (D-1) with low statistical significance (LOD 
<2), and red colour refers to perfect LD (D'=1) with high statistical significance (LOD 
>2), but if the LD is low (D' <1) shades of pink will be used instead. D' is a type of 
statistics for measuring LD. Similar to r2, the range of D' is between 0 and 1; D' =1 is 
perfect LD and indicates that two SNPs have not been separated by recombination. 
b) Haplotypes and their frequencies in each block. 
In block 21, for example there are 4 distinct haplotypes which were generated from 7 
SNPs. Instead of typing all 7 SNPs to identify these haplotypes, genotyping just 2 
SNPs, SNP 218 and SNP 219, can reveal two major haplotypes (89% of the 
population), and if SNP 217 is included, all haplotypes will be disclosed. 
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However, besides recombination which has an important impact on LD, 
many factors are also can influence to the pattern of LD. For example, 
natural selection and genetic drift will increase LD between closely 
linked loci, and population subdivision, population bottlenecks and 
inbreeding can affect LD across the genome, in general resulting in 
increased LD (Slatkin 2008). 
1.3.2 Applications of LD 
The characteristics of LD can be used to map disease genes (or 
traits/phenotypes). This is because disease-causing alleles might also 
have a non-random association with a genetic marker such as a SNP. 
Many studies have now shown that LD can be applied to identify 
disease genes and trait-associated alleles. Examples of such 
successful studies are the discovery of a suspect region for the 
diastrophic dysplasia gene (Hästbacka et a/. 1992) and finding a 
candidate region in Huntington's disease (MacDonald et al. 1992). 
Therefore, it is proposed that LD could be of benefit in genome-wide 
LD mapping to find common disease alleles and in studying population 
history by using a dense map of common SNP markers. 
Currently, with the availability of massive numbers of SNP markers 
from the HapMap (more details are described in 1.2), LD has 
contributed an important tool in genome wide association studies 
(GWAS) to find common alleles or genes which underlie common 
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diseases, with the primary aim of the HapMap to select a set of optimal 
tag-SNPs (as described above). The examples of LD mapping to find 
common disease genes in GWAS include risk factors for type 2 
diabetes in Finns (Scott et al. 2007), GWAS in Parkinson's disease 
(Satake et al. 2009; Simön-Sanchez et al. 2009) and GWAS to identify 
genes for biomarkers of cardiovascular disease (Wallace et al. 2008). 
1.4 CCL3LI and CCL4L1 
1.4.1 The characteristics of CCL3, CCL4, CCL3L1 and CCL4L9 
CCL3, CCL4, CCL3L 1 and CCL4L 1 are chemokine genes located at 
chromosome 17q12. CCL3 and CCL4 are the common ancestral 
genes, and in the reference genome assembly both have a second 
non-allelic copy, CCL3L1 and CCL4LI, originating by segmental 
duplication. Next to them, can also be found a CCL3LI 5'-truncated 
pseudogene (Hirashima at al. 1992; Modi 2004). The map of these 
genes is shown in Figure 1.5. 
14kb 100kb 100kb 14kb 
CCL3 CCL4 CCL3LI CCL4LI CCL3LI CCL4LI 
17g12 
CCL3L7 
pseudogene 
Figure 1.5: Map of CCL3, CCL4, CCL3L1, CCL4L1 and CCL3L1 
pseudogene at chromosome 17g12 [UCSC: Mar. 2006 (NCBI36/HG18)]. 
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CCL3L I and CCL4L I are copy number variable genes. They are highly 
similar to their non-copy number variable paralogues CCL3 and CCL4 
with each pair sharing 95% sequence identity at both the genomic and 
the amino acid levels (Nakao et al. 1990; Modi 2004). 
CCL3 and CCL4 are the abbreviated forms of chemokine (C-C motif) 
ligand 3, and chemokine (C-C motif) ligand 4, respectively. Similar to 
CCL3 and CCL4, CCL3L1 is the abbreviated form of chemokine (C-C 
motif) ligand 3-like 1, and CCL4L1 is the abbreviated form of 
chemokine (C-C motif) ligand 4-like 1. Lastly, CCL3L1 pseudogene or 
CCL3L2 is the abbreviated form of chemokine (C-C motif) ligand 3-like 
2. These chemokines also have alternative names as shown in Table 
1.1. 
Table 1.1: The alternative names of CCL3, CCL4, CCL3L1, CCL4L1 and 
CCL3L2. 
hemokine Alternative name 
CCL3 MIP1A, SCYA3, GOS19-1, LD78ALPHA and 
MIP-1-alpha 
CCL4 ACT2, G-26, LAGI, MIP1B, SCYA2, SCYA4, AT744.1, 
MGC104418, MGC126025, MGC126026 and MIP-1-beta 
CCL3L1 LD78,464.2, CCL3L3, MIPIAP, SCYA3L, GOS19-2, 
CYA3L1, D17S1718, LD78BETA, MGC12815, 
MGC104178 and MGC182017 
CCL4L1 LAG1, CCL4L, LAG-1, CCL4L2, SCYA4L and AT744.2 
CCL3L2 SCYA3L2 and LD78gamma 
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1.4.2 The association between genetic variation at CCL3, CCL4 
and diseases 
Many studies have indicated that polymorphisms in CCL3 and CCL4 
might contribute to diseases. For example, a diversity of 
polymorphisms of CCL3 and CCL4 have been found to be associated 
with HIV infection susceptibility and progression (Modi et a/. 2006). 
Furthermore, Vyshkina and Kalman (2006) found association of 
haplotype 278A-277T with multiple sclerosis in the CCL3 gene. 
1.4.3 The association between genetic variation at CCL3L1, 
CCL4L1 and diseases 
Since the variation of CCL3LI copy number was found, the relationship 
between this gene and diseases in which the gene might play a role 
has been examined. One of the most interesting diseases is HIV 
infection; CCL3L 1 copy number has been now proposed to be a 
genetic determinant of HIV infection (Gonzalez at at 2005; 
Shostakovich-Koretskaya at at 2009). However, there are still some 
controversial issues related to the association between CCL3LI and 
HIV infection such as how to measure CCL3LI copy number 
accurately. More details are described in section 1.4.4. 
In addition, the other diseases in which copy number variation of 
CCL3LI has been implicated are systemic lupus erythematosus (SLE) 
(Mamtani et al. 2008), Kawasaki disease (Burns et al. 2005; Mamtani 
et al. 2010) and chronic hepatitis C (Grünhage et al. 2010). 
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Like CCL3L1, CCL4LI has been found to be associated with HIV 
infection (Colobran et al. 2005). Recently, it has been found that high 
copy number of CCL4L1 is associated with acute rejection in lung 
transplantation (Colobran et al. 2009). 
1.4.4 The association between CCL3L1 and HIV 
1.4.4.1 HIV background 
The identification of genes that are associated with HIV-1 infection and 
AIDS progression has had a lot of attention after "elite controllers" and 
"long-term non progressors" were characterized. These patients show 
resistance to HIV/AIDS; they have low viral load (less than 50 copies 
mL 1 in elite controllers and less than 10,000 copies mL"1 in long-term 
non progressors) despite the absence of antiretroviral therapy (Deeks 
and Walker 2007; Piacentini at a!. 2009). It is these patients that show 
low susceptibility to HIV-1 infection and AIDS progression due to inter- 
individual variability. Consequently, numerous studies in genetic 
association analyses of AIDS have shown that there are several 
genetic factors associated with HIV-1 infection and AIDS progression, 
such as the HLA system (HLA-B*27 and HLA-B*57 alleles (Goulder at 
a!. 1997; Migueles et a!. 2000; Bailey eta!. 2008), HLA-C allele (Fellay 
at aL 2009; Thomas at a!. 2009)), chemokines and chemokine 
receptors (CCL3L1(Gonzalez et al. 2005; Nakajima at al. 2007; 
Shostakovich-Koretskaya et al. 2009), CCR5 (Martin et a!. 1998; 
Mummidi et al. 1998)) and others (Javanbakht et al. 2006; Sobti et al. 
2010). 
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1.4.4.2 CCL3LI and CCR5 receptor 
CCR5 is a chemokine receptor which plays a role in the immune 
system and has been found to be important in AIDS, transplantation 
and cancer (Allen et al. 2007). Many genetic variants within the CCR5 
region have been studied, since this receptor was discovered as a 
major co-receptor for HIV-1 entry to the host cell (Berger et al. 1999; 
Lederman et al. 2006). However, the most investigated genetic variant 
of CCR5 is the loss of function allele CCR5-032, in which 32 bp of the 
coding region of CCR5 are deleted, resulting in a truncated structure 
that no longer functions as a chemokine receptor on the cell surface 
(Silva and Stumpf 2004; Arenzana-Seisdedos and Parmentier 2006). 
This allele, in particular in its homozygous form, is a rare variant in the 
world population (i. e. Homozygosity was found at a 1% frequency in 
the European population only and was not found in Asian and African) 
(Martinson et at 1997). The homozygous carriers of this mutant allele 
show HIV-1 protection, although they are not completely resistant to 
infection (Carrington et at 1999; Sheppard et at 2002). However, there 
is a patient, who has acute myeloid leukemia and HIV-1 infection, who 
was transplanted with stem cells from a CCR5-A32 homozygous donor. 
This patient has still not shown viral rebound for 20 months after 
transplantation, despite discontinuation of antiretroviral therapy (Hutter 
et a/. 2009). The heterozygous carriers of this allele also show slower 
progression to AIDS (Carrington et a/. 1999). In addition, polymorphism 
in the CCR5 promoter region has been found to be associated with 
HIV-1 infection and progression of AIDS, but many of these variants 
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are rare and restricted to specific populations (Arenzana-Seisdedos 
and Parmentier 2006). 
CCR5 is bound and activated by several ligands, including CCL3, 
CCL4, CCL5, CCL8, CCLI 1, CCL14 and CCL16, also known as MIP- 
1a, MIP-10, RANTES, MCP-2, Eotaxin, HCC-1, HCC-4, respectively 
(Allen et a/. 2007). However, the most potent ligand which may also 
have an important role in HIV-1 infection/AIDS is CCL3L1 (Nibbs at al. 
1999). As a result of its copy number variation, the dose of CCL3L1 
binding to CCR5 might have an effect on the susceptibility of HIV-1 
infection and AIDS progression. 
1.4.4.3 CCL3L1 copy number variation and HIV/AIDS susceptibility 
Townson et a/. (2002) initially showed that there are variable numbers 
of CCL3LI and CCL4L1 in the human genome. Moreover, they 
hypothesized that copy number variation in CCL3L1 may affect the 
susceptibility to, or the progression or severity of, disease in which this 
chemokine plays a role. This hypothesis is supported by later studies. 
For example, Gonzalez at a/. (2005) demonstrated that there is copy 
number variation of CCL3L1 between individuals and between 
populations. They also investigated the relationship between copy 
number variation of CCL3LI and susceptibility to HIV/AIDS. The study 
showed that possession of a CCL3L1 copy number lower than the 
population average is associated with increasing susceptibility to HIV-1 
infection and development of AIDS. Nakajima et al. (2007) performed a 
study investigating CCL3LI copy number in long term HIV-1 infected 
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individuals with haemophilia. They found that the average copy number 
of CCL3LI in HIV-1 infected patients was significantly lower than in 
non-HIV-1 infected subjects. However, they did not find the relationship 
between the variation of CCL3L1 copy number and AIDS progression. 
Shostakovich-Koretskaya et a!. (2009) studied the relationship between 
CCL3L1 and CCL4L1 copy number and HIV/AIDS susceptibility in 
Ukrainian children. They also confirmed that the low copy number of 
CCL3L I is related to HIV-1 infection and AIDS progression. Moreover, 
they demonstrated that CCL4LI plays a role in HIV-AIDS susceptibility, 
in addition to CCL3LI, and suggested that the variation in combined 
copy number of CCL3L1 and CCL4LI may determine the susceptibility 
to HIV/AIDS. 
The variation of copy number of CCL3LI is not restricted to humans, 
but it also has been found in macaques. Moreover, the variation of 
CCL3L1 copy number in macaques has been discovered to be 
associated with SIV progression rate, which is similar to the 
relationship between CCL3L1 and HIV-1 infection/AIDS progression in 
humans, and monkeys with lower CCL3L I copy number have a more 
rapid progression of simian-AIDS than those with higher CCL3L1 copy 
number (n=57) (Degenhardt et at 2009). 
The relationship and mechanism between CCL3L1 and CCR5's ability 
to inhibit HIV-1 infection and/or to slow the progression of AIDS is still 
unclear but many proposals have been put forward (Mackay 2005). 
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One possible hypothesis is that CCL3L1 binds to CCR5 and blocks the 
binding site for HIV-1. The second possibility is CCL3L1 might affect 
CCR5 expression by down regulation of CCR5 from leukocytes. Lastly, 
CCL3LI might cause quantitative or qualitative changes in leukocyte 
recruitment. However, Dolan et al. (2007) demonstrated that CCL3LI 
and CCR5 variations influence cell-mediated immunity (CMI) and affect 
HIV pathogenesis via viral entry-independent mechanisms. 
Although the exact mechanism by which CCL3L1 copy number and 
CCR5 genotype respectively may act against HIV-1 infection and AIDS 
progression is still unknown, Gonzalez et al. (2005) investigated risk of 
HIV-1 infection and rates of AIDS progression by grouping individuals 
based on CCR5 genotype and CCL3L 1 copy number. They created 
three genetic risk groups; high risk group (low CCL3L 1 copy number 
and detrimental CCR5 variations), low risk group (high CCL3LI copy 
number and non-detrimental CCR5 variations) and moderate risk group 
(high CCL3L1 and detrimental CCR5 variations or low CCL3L1 copy 
number and non-detrimental CCR5 variations). Kulkarni at al. (2008) 
demonstrated that these genetic risk stratifications might be useful in 
improving the assessment of AIDS risk in HIV-1 infected individuals. 
They claimed that the combination of the laboratory markers (such as 
CD4 cell count and viral load) and CCL3L 1-CCR5 genetic markers will 
provide more prognostic information in HIV/AIDS than either marker 
alone. 
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Recently, two independent studies that used a modified real-time PCR 
assay, failed to replicate the results that CCL3L 1 copy number is 
associated with HIV-1 acquisition, viral load and AIDS progression 
(Bhattacharya et al. 2009; Urban et al. 2009). Furthermore, a study that 
compared two assays, PRT and real-time PCR, to measure CCL3L I 
gene copy number (Field et a/. 2009). This study suspected that real- 
time PCR assays might provide an over-estimate of CCL3L 1 copy 
number. In reply, He of al. (2009) explained that using a different label 
in the real-time PCR assay might explain the different results and 
suggested that it is important to count the CCL3L 1 pseudogene, also 
known as CCL3L2, to give the correct copy number for CCL3LI. This 
issue of inconsistent copy number measurement is not limited to 
humans. Perry of al. (2008) used array CGH and found that 
chimpanzees have two copies of CCL3LI per diploid genome, whilst 
Degenhardt of al. (2009) used real-time PCR and found that CCL3L1 is 
a copy number variable gene in chimpanzees with a mean copy 
number at 14.58. 
Understanding how to measure the copy number of the CCL3LI gene 
accurately is essential to be able to investigate the relationship 
between this gene and HIV/AIDS. 
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1.5 The objectives of the study 
The main objectives of this research are as follows: 
9 To understand the structure of the variable CCL3L 1/CCL4L I 
region by investigating variants in this region. Also, to 
understand the evolutionary history of variation at the 
CCL3L 1/CCL4L I cluster. 
9 To develop an assay for the presence of the CCL3L I 
pseudogene, and to investigate European (ECACC and CEPH 
HapMap), Asian (CHB/JPT) and African populations (YRI) for 
the presence of this pseudogene. 
" 
To investigate an association between presence/absence of the 
CCL3L I pseudogene and CCL3L I/CCL4L I copy number in 
European (ECACC and CEPH HapMap), Asian (CHB/JPT) and 
African populations (YRI). 
9 To develop assays for known variants within the repeat, and for 
variable sites flanking the region of CCL3L 1/CCL4L 1. Then, use 
these single SNP markers and CCL3 microsatellite to examine 
for associations with CCL3L1/CCL4L1 copy number in 
European (ECACC and CEPH HapMap), Asian (CHB/JPT) and 
African populations (YRI), and investigate again for SNPs that 
could potentially predict CCL3L1/CCL4LI copy number. 
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" 
To sequence CCL3L 1/CCL4L I and define the haplotype 
background of each of CCL3LI/CCL4LI copy. After that, look 
for SNPs or haplotype blocks using LD analysis, and, again 
examine their potential in prediction of CCL3L1/CCL4LI copy 
number. 
" To investigate association between CCL3LI/CCL4LI copy 
number and tuberculosis. 
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Chapter 2: Materials and Methods 
2.1 Genomic DNA samples 
2.1.1 ECACC Human Random Control (HRC) samples 
In this study, ECACC HRC DNA Panel I and 2 were purchased from 
the Health Protection Agency Culture Collections 
(http: //www. hpacultures. org. uk/). This DNA was extracted from 
randomly selected unrelated UK Caucasian blood donors. 
2.1.2 HapMap samples 
All HapMap samples which were used in this study (including CEPH 
HapMap, CHB/JPT and YRI samples) were obtained from the Coriell 
Institute for Medical Research 
(hhf : //ccr. coriell. or4/Sections/Collections/NHGRI/haRma2. aspx? Pgld=2 
66&coll=HG). The CEPH HapMap and YRI samples comprise 30 
parent-offspring trios and CHB/JPT samples include 45 unrelated 
Japanese from Tokyo and 45 unrelated Han Chinese from Beijing. 
2.1.3 CEPH samples 
A number of CEPH samples from the Centre de'Etude du 
Polymorphism Humain (CEPH) (hftl2: //www. gtph-b-fr-/) collection were 
specifically selected to type their CCL3LI/CCL4LI copy number, and 
to deduce unambiguously their CCL3LI/CCL4LI copy number 
haplotype in which microsatellite segregation analysis was 
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uninformative. The selected CEPH families and their number in the 
pedigree are shown in Table 2.1. 
Table 2.1: The list of selected CEPH families and their individual 
number in the pedigree. 
CEPH family number Number in the pedigree 
1341 3,4,5,6,8 
1344 2,7,8,9 
1345 1,4,5,9,10,11 
1347 1,10,11,16 
1350 5,6 
1362 4,5,7 
1408 3,8,4 
2.1.4 Basque samples 
The origin and DNA extraction method of Basque individual DNA 
samples were described in Alonso and Armour (1998). 
2.1.5 Tuberculosis (TB) case-control analysis samples 
The DNA from Tuberculosis (TB) case-control analysis samples were 
kindly supplied by our collaborators, Dr. Jon Goulding and Prof. Mike 
Levin (imperial College, London). Briefly, These samples are TB 
paediatrics-matched controls collected from African population (i. e. 
! Xhosa); all samples were diagnosed for TB including medical history, 
a physical examination, a chest X-ray, microbiological examination and 
Mantoux test (personal communication). 
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2.2 Polymerase Chain Reaction (PCR) 
2.2.1 Primer design 
PCR primers were designed using the UCSC genome browser March 
2006 (NCBI36/HG18) assembly 
_htt 
: // enome. ucsc. edu/index. html? ora=Human&db=hg18&hgsid=184 
944801) using the Primer 3 programme 
(http: //frodo. wi. mit. edu/primer3/). Suggested PCR primers were 
checked using in-silico PCR available on UCSC genome browser to 
assure that the PCR primers were specific and produced only the 
target products. The sequences of PCR primers were also checked to 
confirm that they did not include common substitution variants by 
searching BLAST Human Sequences from NCBI 
(http: //www. ncbi. nim. nih. gov/genome/sea/BlastGen/BlastGen. cgi? taxid 
=9606). 
2.2.21Ox "LD" PCR buffer and IOx PCR buffer 
1 Ox "LD" PCR buffer OR 1 Ox PCR buffer 2 NI 
10 pM forward primer I ui 
10 pM reverse primer I NI 
5U/pl Taq DNA polymerase 0.2 PI 
H2O 14.8 p1 
10 ng/pI DNA 1 NI 
Total 20 NI 
Unless stated otherwise, all PCR products were amplified using the 
above mixture with 10x "LD" PCR buffer with the exception of CCL3L I 
and CCL4L 1 products which utilised 10x PCR buffer. 
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The 1 Ox "LD" PCR buffer consists of final concentrations of 50mM Tris- 
HCI pH8.8,12.5 mM (NH4)2SO4,1.4 mM MgC12,7.5 mM 
2-mercaptoethanol, 125 pg/ml Bovine serum albumin (BSA) and 
200 pM of each dNTP. The 10x PCR buffer consists of final 
concentrations of 50mM Tris-HCI pH8.8,12 mM (NH4)2SO4,5 mM 
MgCl2,7.4 mM 2-mercaptoethanol, 125 pg/ml Bovine serum albumin 
(BSA) and 1.1 mM each dNTP. 
2.2.3 Primers and PCR conditions for CCL3L1 pseudogene assay 
The primers that were used in this assay are shown in Table 2.2, and 
the amplification protocol for this reaction was 5 minutes of initial 
denaturation at 95°C, followed by 37 amplification cycles (1 minute of 
denaturation at 95°C, 1 minute of annealing at 60°C and 1 minute for 
extension at 70°C). 
Table 2.2: CCL3LI pseudogene assay primers. 
Primer name Primer sequence (5'-3') 
CCL3F TGGCTGCTCGTCTCAAAGTA 
CCL3R AATTCCCTGAAGAGAACTGAGA 
CCL3PR GTGTGCAAGGACAATGCAAG 
2.2.4 Primers and PCR conditions for CCL3LI and CCL4LI 
sequencing analysis 
The primers and conditions used in CCL3LI and CCL4LI sequencing 
analysis are shown in Tables 2.3 to Table 2.5. 
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Table 2.3: CCL3LI PCR amplification and sequencing primers. 
Primer name Sequence (5'-3') 
CCL3LI Fl TCCTAGAGCGTGCATATTACGA 
CCL3L1 F2 CACACGCATGTTCCCAAG 
CCL3LI F3 GAGGTGAGCAGGAAGACTGG 
CCL3LI F4 AGGGTGAGCTGGAGAGTGAA 
CCL3LIR AAAGAGGAGAGATGGCTTCAGA 
Table 2.4: CCL4LI PCR amplification sequencing primers. 
Primer name Sequence (5'-3') 
CCL4LIF1 CCTCCTTTTTAAAGGCATTTTT 
CCL4L1 F2 GACAGGAACTGCGGAGAGG 
CCL4L1 F3 TCCATATCTCACGGGACCT 
CCL4LI F4 CCATTCCCACCTAACATGAG 
CCL4L1F5 CAGTCACGCAGAGCTTCAT 
CCL4LI R CTGGTTCCCGCTTTGTTCT 
Table 2.5: The conditions of CCL3LI and CCL4LI PCR amplification. 
PCR Denaturing Annealing Extension Cycles 
name Temp. 
(°C) 
Time 
(s) 
Temp. 
(°C) 
Time 
(s) 
Temp. 
(°C) 
Time 
(a) 
CCL3L1 95 30 57 30 70 180 40 
CCL4L1* 95 30 56 30 70 180 40 
Note: *Pre-denaturing at 95°C for 5 minutes was used before the 
cycles of PCR. 
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2.2.5 Primers and PCR conditions for testing of somatic variation 
and mixed samples 
The primers and conditions used in this assay were modified from 
Kimpton et al. (1996). The primers are shown in Table 2.6, and the 
primers used fluorescent dyes as indicated on their primer names. 
A PCR was performed in lx LD buffer using 5 ng genomic DNA and 
0.5 U Taq DNA polymerase in a total volume of 10 pl. Products were 
separately amplified with 1 pM each of FAM-DI8S51 F and D18S51 R, 
or D21 S 11 F and FAM-D21 S 11 R for 26 cycles of 93°C for 30 seconds, 
58°C for 1 minute and 15 seconds, 72°C for 15 seconds followed by a 
final hold at 72°C for 10 minutes. 
Table 2.6: Microsatellite analysis primers (testing for somatic variation 
and mixed samples). 
Primer name Primer sequence (5'-3') 
FAM-D18S51 F CAAACCCGACTACCAGCAAC 
D18S51R GAGCCATGTTCATGCCACTG 
D21S11F ATATGTGAGTCAATTCCCCAAG 
[AM-D21S11 R TGTATTAGTCAATGTTCTCCA 
Note: FAM is the abbrevia ted form of Fluorescein amidite and used as 
fluorescein-labeled oligonucleotide probe. 
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2.3 DNA Sequencing 
PCR products were purified using AMPure®XP (Agencourt®) according 
to the manufacturer's protocol prior to sequencing with Big Dye® 
Terminator v3.1 Cycle Sequencing Kit (Applied BiosystemsTM) as the 
following mixture: 
Big Dye® Terminator v3.1 Cycle Sequencing 
5x Sequencing buffer* 
10 pM primer 
H2O 
10-20 ng/pl DNA 
1 PI 
2 NI 
0.5 NI 
4.5 NI 
z NI 
Total 10 NI 
*The sequencing buffer is composed of 250 mM Tris-HCI pH 9 and 
10 mM MgCI2. 
Sequencing reactions were carried out as follows: 25 cycles of 96°C for 
30 seconds, 50°C for 15 seconds and 60°C for 4 minutes, after which 
sequenced products were cleaned to remove unincorporated dyes 
using CleanSEQ® (Agencourt®) following the manufacturer's 
instructions. Lastly, all PCR products were sent to DBS genomics, 
School of Biological and Biomedical Sciences, Durham University for 
capillary electrophoresis and data collection on ABI 3730 DNA 
Analyser. 
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2.4. SNP assays 
The SNPs that were investigated can be divided into three categories: 
SNPs within the CCL3 region, SNPs at CCL3L1 and CCL4L1, and 
additional SNPs within chromosome 17q12. The list of SNPs in each 
group is shown in Tables 2.7-2.9 and Figures 2.1-2.3, respectively. 
SNPs within the CCL3 region were selected from the HapMap 
database (http: //hapmap. ncbi. nlm. nih. aov/) using the following criteria: 
" 
They are located within the CCL3 region 
(Chr. 17: 31,435,952-31,444,611). 
" They are not located in a repeat sequence such as long 
terminal repeat (LTR). 
" They have an average heterozygosity greater than 0.35. 
" They are not associated with another chosen SNP which 
were also used in the SNP assays. 
About 4kb CCL3 About 3kb About 14kb CCL4 
17g12 
' rs 1851503 I' rs 1634502 
rs1634492 rs9972960 
rs 1130371 & rs 1804185 
Figure 2.1: The positions of SNPs that were examined within the CCL3 
region. 
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SNPs at CCL3LI and CCL4LI were selected from UCSC Genome 
Browser March 2006 assembly (http: //qenome. ucsc. edu/) using the 
following criteria: 
" 
They are located in the CCL3LI (Chr. 17: 31,546,382- 
31,548,269 or 31,647,956-31,649,843) and CCL4LI 
(Chr. 17: 31,562,581-31,564,387 or 31,664,147- 
31,665,959). 
" 
They are not located in a constant region. 
14kb 100kb 100kb 14kb 
oil 0 
CCL3 CCL4 CCL3L1 CCL4LI CCL3LI CCL4LI 
17g12 
CCL3L1 
pseudogene 
rs2277661 
.................................. .................................. 
rs3744594 & rs4796195 
Figure 2.2: The positions of SNPs that were examined at CCL3L1 and 
CCL4L 1. 
36 
The additional SNP assays within chromosome 17q12 were selected 
from linkage disequilibrium analysis results that showed these SNPs 
might have an association with CCL3L1/CCL4L1 copy number. 
100kb 100kb 240kb 
CCL3 CCL4 CCL3L 1 CCL4L 1 CCL3L I CCL4L 1 
17g12 
CCL3L 1 -' 
pseudogene 
rs12453313 
rs9910447 
rsl 6972085 
rs8070238 
rs8064426 
rs868340 
Figure 2.3: The positions of additional SNPs that were examined 
within the Chr. 17q12 (These SNPs were suggested by Dr. Danielle 
Carpenter (personal communication), except SNP rs12453313 and 
rs9910447). 
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After all SNPs had been selected, the PCR primers were designed, to 
have the following characteristics using Primer3 software programme 
(http: //frodo. wi. mit. edu/). 
9 The primers should not include a known SNP position 
themselves. 
9 The sequence of primers should be designed to 
discriminate against their paralogous sequence to avoid 
co-amplification. 
For example, the SNP assay for rs1634492 within CCL3 region has a 
similar sequence to its paralogue, CCL3L1. Therefore, the primers for 
this SNP should specifically amplify CCL3 only and not CCL3L1. As a 
result, the primers were designed to have mismatches with the 
CCL3L1 consensus sequence in both forward and reverse primers. An 
alignment of CCL3 with CCL3L1 is shown in Figure 2.4. Moreover, the 
PCR products were checked to confirm the products were CCL3 and 
not from CCL3L1 using the restriction enzymes, BsrGl and Tail. This 
PCR product is 365bp. The CCL3 product will be digested into 29bp + 
336bp fragments. If the products derived from CCL3LI, the product will 
be cut into 191 bp + 174bp fragments. 
All PCR products were pre-tested to confirm the identity of the product 
by digestion with diagnostic restriction enzymes as mentioned above. 
Then, all SNPs were genotyped by PCR-RFLP technique. 
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BsrGI 
CCL3 
_ccctgcagaaaatgaa, oaa. ggattcatgt. acactggcaggtactggc CCL3 
»»»» III IIIIIIIIIIIIIIII IIIIIIIIII IIIIIIIIIIIIIIIIII »»»» 
CCL3L1 tccttgcagaaaatgaacaaaggattcatgtaacactggcaggtactggc CCL3L1 
CCL3 agccacccagggcctctcacaggaaagggagatcagaaagagaagcaaag CCL3 
»»»» IIIIIIIIIPIIIIPIIIIIIIIIIIIIIIIIIPIIIIIIIIIIIIIIII »»»» 
CCL3L1 agccacccagggcctctcacaggaaagggagatcagaaagagaagcaaag CCL3L1 
CCL3 aggactcatgagataccacagggccgctgagtccagccttgcctggagct CCL3 
»»»» IIIIIIIIIIIIIIIIH IIIII IIII PIIIIIIIIIIIIIIIIIII »»»» 
CCL3L1 aggactcatgagataccatagggctgctgcgtccagccttgcctggagct CCL3L1 
CCL3 agggccacctcgatgccctatagtcttggagccacaaggtgcatttactc CCL3 
»»»» IIIIIIIIIilllllllllllllllllllllHIHI IIIIIIIIIIII »»»» 
CCL3L1 agggccacctcgatgccctatagtcttggagccacaacgtgcatttactc CCL3L1 
Tail 
CCL3 aaagcctctttgagtttggtttgcttgtttgctttctgcctggaaactgc CCL3 
»»»» IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII »»»» 
CCL3L1 aaagcctctttgagtttggtttgcttgtttgctttctgcctggaaactgc CCL3L1 
CCL3 cagcatcctgagagatacgagatctgcatctgtgcagagacacagggttt CCL3 
»»»» IIIIIIIIIIIIIIPIIIIIIIIIIIPIIIIIIIIIIIIIIIIIIIIIII »»»» 
CCL3L1 cagcatcctgagagatacgagatctgcatctgtgcagagacacagggttt CCL3L1 
CCL3 gttaaaagtcacaggccctgactgaagtgtggaactggctgaaaLgacaa CCL3 
»»»» IIIIIIPIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIP »»»» 
CCL3L1 gttaaaagtcacaggccctgactgaagtgtggaactggctgaaatgagaa CCL3L1 
CCL3 agtaoc=..; a a tttgg CCL3 
»»»» III IIIIIIIIII »»»» 
CCL3L1 agt.... ggtaatttgg CCL3L1 
Figure 2.4: Alignment of CCL3 with CCL3LI for designing the primers 
at SNP rs1634492. 
The primers are shown in blue and the restriction sites for SsrGI and 
Tail are shown in red. 
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The assay for rs1634492 will be described in detail below as an 
example of a typical method for SNP typing. Most SNP assays were 
carried out in a similar way to SNP rs1634492 assay, except that the 
SNP assay for rsl 130371 and rsl 804185 used one restriction enzyme 
to assay two SNPs simultaneously. 
All information for the SNP assays such as name of SNPs, the 
positions in the genome, primers that were used, PCR product sizes, 
and PCR conditions are shown in Tables 2.7-2.10. 
2.4.1 SNP assay for rs1634492 
PCR products were amplified with the primers and conditions as shown 
in Tables 2.7 and 2.10, respectively. The expected size of products is 
365bp. This was verified by 1.5% agarose gel electrophoresis of PCR 
products. The PCR products were then digested with the restriction 
enzyme Hinfl. In a digestion, 8µI of PCR product was added to a 12µI 
digestion solution containing 9.5µI of purified water, 2µI of IOxNEBuffer 
2 (NEB) and 5U Hinfl. After incubation at 37°C overnight, the sizes of 
the PCR products were re-checked again by 2.5% agarose gel 
electrophoresis, and showed one of these four possible types: 
" Incomplete digestion = 365bp 
" 
Homozygous (C/C; no variable site) = 263bp fragment 
" 
Homozygous (A/A; has variable site) = 237bp fragment 
" 
Heterozygous (C/A; one allele has variable site and the other 
one does not) = 237bp and 263bp fragments 
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The sequence of the PCR products (M =A or C) is: 
TC CCTG CAGAAAATGAACAAggattcatgtacactggcaggtactggcagccaccc 
agggcctctcacaggaaagggagatcagaaagagaagcaaagaggactcatgagataccac 
agggccgct 
gM gtccagccttgcctggagctagggccacctcgatgccctatagtcttggagccacaaggtgc 
atttactcaaagcctctttgagtttggtttgcttgtttgctttctgcctggaaactgccagcatcctgaga 
gatacgagatctgcatctgtgcagagacacagggtttgttaaaagtcacaggccctgactgaagt 
gtggaactggctgaaaTGAGAAAGTAGGAGGTAATTTGG 
The PCR product generated includes two non-polymorphic Hinfl sites 
(see above, GAnTC in blue), so that if digestion is complete, all 365bp 
products should be cut into 23bp + 342bp fragments, and the 342bp 
fragment will further cut into 79bp + 263bp fragments. If the variable 
Hinfl site is present (i. e. if M=A in GMgTC in red above), all 263bp 
fragments should be cut into 26bp + 237bp fragments. 
2.4.2 SNP assay for rs1130371 and rs1804185 
This assay combines two SNP assays. The SNP rs1130371 was 
selected from the HapMap database and the SNP rs1804185 was 
selected from the UCSC genome browser. The SNPs are just 60bp 
apart so it is beneficial for both SNPs to be genotyped simultaneously 
using the same restriction enzyme. Fortunately, NcRl can be used to 
investigate both SNPs. However, the assay had to construct a NO 
constant site for use as a control for complete digestion by designing a 
mismatch into the forward primer. 
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The sequence of the PCR products (Mismatched primer base in green; 
Y=CorT, R=AorGandS=GorC)is: 
CCCTTTCCTCTGGG CCGGggcagcccttcctgactctgtaacacatgcctcactccag 
ctccaagtcaggtcacacctcgg agccctgcgtcctgtatccccgataggctcctgaagg ctg gg 
cctttccaggatggccttctggcctgtctctgccccaaccctg accctccctacctccatagaggtga 
gcaggaagactggcacttacatgacaccYggcttggagcactggctgctcgtctcaaagtagtc 
agctatgaaattctgtggaatctgccgg Raggtgtagctgaagcagcaggcggtcggcgtgtca 
gcagcaactgtggagaaaggaagagaataagcccgagtcacagctcagaagaaaaggcca 
ggcagcttctgatccccgagcagttgaggaaggcaggcttgctcagaccaagtgactggaagg 
CATTTGGGCATTTTTGCTG 
The PCR product generated includes a non-polymorphic Ncil site (see 
above, ccsgg in blue), so that if digestion is complete, all 461 bp 
products should be cut into 17bp + 444bp fragments. If the first variable 
Ncr1 site is present (see above, ccYgg in red), all 444bp fragments 
should be cut into 203bp + 241 bp fragments. If the second variable Ncil 
site is present (see above ccggR in red), all products should further cut 
241 bp fragment into 62bp + 179bp fragments. 
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2.5 Allele-specific PCR assays 
All allele-specific primers and conditions used at CCL3L1 and CCL4L1 
are shown in Tables 2.11-2.12. The denaturing and extension 
temperature for all primers are 95°C and 70°C, respectively, and all 3 
steps of the PCR cycle used 30 seconds in each cycle of PCR. Due to 
the length of allele-specific PCR products, sequencing using an 
additional primer was used to obtain full length sequence of the 
product. More details of the assays are explained in the section 5.4. 
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2.6 Emulsion haplotype fusion PCR 
Emulsion haplotype fusion PCR is a technique, published by Turner 
and Hurles (2009), to determine haplotypes over long distances. In this 
study, emulsion haplotype fusion PCR was developed and optimized 
by Dr. Jess Tyson (personal communication) to determine the phase 
for haplotypes of CCL3L 1/CCL4L 1. The principle of emulsion haplotype 
fusion PCR is shown in Figure 2.5. 
To achieve CCL3L I/CCL4L I phased haplotypes by using emulsion 
haplotype fusion PCR, PCR amplification was done in two stages. The 
first PCR amplification was performed in emulsion droplets to produce 
fused products from two loci, CCL3L1 and CCL4LI, and the second 
PCR amplification was performed in a similar manner to allele-specific 
PCR to construct a PCR product that once sequenced would reveal the 
variant bases on the same haplotype. In some samples, a third PCR 
amplification was needed using an additional primer to obtain the full 
length sequence of the product. 
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a) 14kb 1 00kb 100kb 14kb 
CCL3 CCL4 CCL3LI CCL4LI CCL3LI CCL4LI 
17g12 
CCL3L 1 
pseudogene 
F 
IN. [CR] "F0. [C/ ] 
......... 
b) 
[G/A] [G/A] R2 
R1 F2' 
F1 [CM 
i 
-10- [G/A] R2 
[G/AI R1F2' 
dý Fl [C/21 
[G/AI R2 
eý Fl [Cn7 [2f2 
[G/A] [G/A] R2 
Figure 2.5: Emulsion haplotype fusion PCR. a) Diagram of CCL3L 1 and CCL4LI at 
Chr. 17g12; they are about 14kb apart. b) The primer F1 is the forward primer which 
was designed to be specific for the CCL3LI locus, and R2 is the reverse primer which 
was designed to the locus on CCL4LI. F2, which in typical PCR is the forward primer 
for CCL4L1 locus, was designed to be a reverse complementary sequence to append 
to the 5' end of primer R1, which is then called the fusion primer R1 F2'. The variant 
bases are indicated symbolically in both loci. c) PCR products from both loci were 
produced. d) The CCL3L1 PCR product can prime on the PCR product from CCL4LI 
since the tail on the fusion primer matches the reverse complement of F2 from 
CCL4L1 locus. e) The fused PCR product was amplified by the primers F1 and R2. 
Then, the variant bases from both loci of CCL3LI and CCL4LI can be defined as a 
CCL3LI/CCL4LI haplotype using allele-specic PCR and sequencing. 
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The first PCR amplification, which was done in emulsion droplets, was 
composed of an aqueous phase and an oil phase. The aqueous phase 
contained the following 
5x GC buffer (Phusion®) 20 NI 
10mM dNTPs 2 NI 
10 pm forward primer (F1) 10 NI 
1 pm fusion primer (R1-F2') 2.5 NI 
10 pm reverse primer (R2) 10 NI 
2U/pl Phusion® DNA Polymerase 7 NI 
H2O 47.5 NI 
200 ng/pI DNA 1 NI 
Total 100 NI 
To create emulsion droplets, 10 pl prepared aqueous phase was 
pipetted dropwise every 5 seconds to 200 pl oil phase (including 9 pl 
Span 80 (Sigma, cat. no. S6760), 0.8 pl Tween 80 (Sigma, cat. no. 
P8074) and 1 pl Triton X-100 (Sigma, cat. no. T9284) in 200 pl of light 
mineral oil (Sigma, cat. no. M5904)) while stirring at 1000 rpm with a 
magnetic stirrer. 100 pl mixture was aliquoted into 0.5 ml tubes and 
amplified at 98°C for 30 seconds followed by 40 cycles of 98°C for 10 
seconds and 72°C for 45 seconds, followed by 72°C for 5 minutes, and 
a 4°C hold. 
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The fusion PCR products were extracted from emulsion droplets by 
mixing with an equal volume of hexane, vortexing and centrifuging at 
13,000g for 3 minutes. The oil phase was removed and the hexane 
extraction was repeated for an additional 2 times or until the layer 
between oil phase and aqueous phase was extremely thin. Finally, the 
fusion PCR products in aqueous phase were diluted to 1: 10 with water 
for the second round of PCR. 
The second PCR was carried out using the mixture described below. 
1 Ox NH4 buffer (Bioline®) 1.9 NI 
50 mM MgCI2 0.8 NI 
25mM dNTPs 0.16 NI 
10 pM forward primer (F1) 1 NI 
10 pM reverse primer (R2) 1 NI 
5U/pI Taq DNA Polymerase 0.2 NI 
H2O 13.94 NI 
1: 10 dilution of I't round PCR product 1 NI 
Total 20 NI 
The primers and conditions used in both rounds of PCR are shown in 
Table 2.13 and Table 2.14. 
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2.7 Triplex PRT PCR assay 
PRT is an abbreviation of Paralog Ratio Test, which is a technique to 
measure copy number. In brief, this technique uses a single pair of 
specifically designed primers to amplify two products from a copy 
number variable site of interest, called the test region, and a reference 
locus simultaneously. Then, the copy number of the test region is 
inferred from the ratio of test to reference products (Armour et al. 
2007). 
The triplex PRT PCR assay was developed based on the PRT 
technique designed by Susan Walker (Walker 2009; Walker et al. 
2009). The assay combined 3 systems, including CCL3C, CCL4A and 
LTR61A as shown in Figure 2.6. 
14kb 100kb 100kb 14kb 
CCL3 CCL4 CCL3LI CCL4LI CCL3LI CCL4LI 
17q12 
LTR61 LTR61 
CCL3C 
Figure 2.6: Schematic diagram of triplex PRT system. 
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CCL4A LTR61A 
The aims of CCL3C and CCL4A systems are to measure the copy 
number of CCL3LI and CCL4LI relative to their paralogues CCL3 and 
CCL4. For LTR61A, the system is specially designed to measure a 
Long Terminal Repeat located between CCL3LI and CCL4LI relative 
to a homologous sequence on chromosome 10 at an unlinked 
reference locus known to be a single copy region. The advantage of 
including this system in triplex PRT PCR assay was to confirm the copy 
number of CCL3L1 and CCL4LI determined by those two systems. 
Moreover, it would help to detect any copy number variation in CCL3 
and CCL4 regions. 
Here, the triplex PRT PCR assay was applied, mainly to determine 
CCL3LI and CCL4LI copy numbers in paediatric tuberculosis case- 
control analysis samples, with some modifications to the protocol as 
described below. 
A PCR was performed in 1x LD buffer using 5 ng genomic DNA and 
0.5 U Taq DNA polymerase in a total volume of 10 pl. Products were 
amplified with 0.5 pM each of FAM-CCL3CF, CCL3CR, FAM-CCL4AF 
and CCL4AR and 1.5 pM of FAM-LTR61AF and LTR61AR for 23 
cycles of 95°C for 30 seconds, 55°C for 30 seconds, 70°C for 1 minute 
followed by a final hold at 70°C for 40 minutes. Sequences of all 
primers are shown in Table 2.15. 
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Table 2.15: Sequence of triplex PRT PCR primers. 
Primer name Primer sequence (5'-3') 
CCL3CF GGCTAAGACCCCTTCTAGAG 
C AATCATGCAGGTCTCCACT 
rCCL4AF GAGTCTGCTTCCAGTGCT 
rCCL4AR GAGGAGTCCTGAGTATGGAG 
LTR61AF AGTTTTCCTCTGCCTAGC 
LTR61AR TATTTATTTTAAGGTGTGCAC 
For each sample, the PCR was carried out in triplicate as described 
above, substituting FAM-labelled forward primers with HEX and NED 
labelled primers. Fluorescently labelled PCR products were analyzed 
by capillary electrophoresis on an AB13100 36 cm capillary using 
POP-4 polymer with an injection condition of 2kV for 45 seconds. I NI 
of each fluorescently labelled PCR product was mixed with 1 Opi Hi-DiTM 
Formamide (Applied Biosystems) and ROX-500 marker (Applied 
Biosystems) and denatured at 95°C for three minutes prior to 
electrophoresis. 
Finally, Genescan software (Applied Biosystems) was used for data 
analysis. The heights of test and reference peaks for each of the three 
systems were collected and used to calculate the ratio of test/reference 
signals. The average of the ratio of the three fluorescent dyes of each 
system was used to infer the copy number for each system in each 
sample using reference standards as calibration. 
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Chapter 3: CCL3L1 pseudogene assay 
3.1 Introduction 
Pseudogenes are defective copies of regular genes. Generally, they 
are not functional because they are unable to be transcribed or 
translated. However, some pseudogenes can be transcribed and have 
a function (Hirotsune at al. 2003; Zheng at al. 2005). There are about 
20,000 pseudogenes in the human genome (Harrison et a1.2002; 
Zhang at al. 2003). 
The CCL3L I pseudogene is a 5' truncated copy of CCL3L I located at 
chromosome 17q12 (Hirashima et at 1992; Modi 2004). It is also 
known as GOS19-3; SCYA3L2; LD78gamma and CCL3L2 
(htta: //www. ncbi. nlm. nih. gov/gene/390788). This pseudogene has 
sequences similar to CCL3LI gene, but is lacking exon 1 of CCL3L1 
(Figure 3.1) (Hirashima et al. 1992; Modi 2004). As a result, it might 
cause problems with measurement of CCL3L I copy number by 
CCL3L I pseudogene acting as a template for the PCR for the CCL3L 1 
gene (Field et a/. 2009). Consequently, it might affect the interpretation 
in an association study between CCL3L 1 gene and diseases 
(Gonzalez et al. 2005; Field et al. 2009; Shostakovich-Koretskaya et al. 
2009). 
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The aims of this study were to study the presence of the pseudogene 
in populations, to investigate the association between CCL3L1 
pseudogene and the copy number of CCL3L1/CCL4L1, and to observe 
the patterns of this association in different populations. To accomplish 
the objectives, reliable assays for detection of the CCL3L 1 
pseudogene, which can distinguish between this pseudogene and 
CCL3LI gene, were constructed and applied in HapMap samples, 
including CEPH samples, Chinese-Japanese samples and Yoruba 
samples, and ECACC (UK) samples. The PCR assay for CCL3LI 
pseudogene is shown in Figure 3.1. 
CCL3 CCL4 CCL3L 1 CCL4L 1 CCL3L 1 CCL4L1 
17q12 
CCL3L7 
pseudogene 
Exon 3 Exon 2 Exon1 Exon 3 Exon 2 Exon 3 Exon 2 Exon 1 
CCL3F CCL3F CCL3F 
17q12 
............ 
CCL3R CCL3PR 
Figure 3.1: The structure of CCL3L9 pseudogene and CCL3L1 and 
CCL3L1 pseudogene assay. 
PCR products were amplified with the control primers, forward primer 
CCL3F and the reverse primer CCL3R, making a 358bp product 
specific to CCL3 gene, and the alternative reverse primer CCL3PR, 
making a 233bp product specific to the DNA sequence around the 
novel junction created by the pseudogene duplication. The expected 
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size of products from CCL3 is 358bp, and products at 233bp indicated 
the presence of CCL3L1 pseudogene. This was checked by 1.5% 
agarose gel electrophoresis as examples are shown in Figure 3.2. 
Then, the association between CCL3L1 pseudogene and the copy 
number of CCL3LI/CCL4LI was performed by using a Chi-square (x2) 
test. 
Human genomic DNA 
100 bp 
marker 
500bp 
400bp -+ 
300bp ýº 
200bp 
-0' 
100bp 
358bp (CCL3) 
233bp(CCL3L1 pseudogene) 
Figure 3.2: Examples of CCL3LI pseudogene assay. 
The PCR products from CCL3 gene appear at 358bp, and the PCR 
product at 233bp indicates the presence of CCL3LI pseudogene. 
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3.2 ECACC (UK) samples 
3.2.1 CCL3LI pseudogene in ECACC (UK) samples 
Using the above assay, The CCL3LI pseudogene was investigated in 
192 ECACC (UK) samples, and it was found in 52 out of 192 samples 
(about 27%). 
3.2.2 The relationship between CCL3Li pseudogene and 
CCL3L1/CCL4LI copy number in ECACC (UK) samples 
The relationship between the presence of the CCL3L 1 pseudogene 
and the copy number of CCL3LI/CCL4LI was further investigated in 
192 ECACC (UK) samples. The results are shown in Tables 3.1-3.3. 
Table 3.1: The presence of CCL3L1 pseudogene and the copy number 
of CCL3LI/CCL4LI in ECACC (UK) samples. 
Copy number of CCL3L 1/CCL4L 1 0 1 2 3 4 
CCL3L I pseudogene present 0 4 14 29 5 
CCL3L 1 pseudogene absent 2 29 102 7 0 
Total (samples) 2 33 116 36 5 
Table 3.2: The presence of CCL3L1 pseudogene and the copy number 
of CCL3LI/CCL4L I in ECACC (UK) samples (grouped for x2 test). 
Copy number of CCL3L 1/CCL4L 1 1-2 3 4 
CCL3L I pseudogene present 18 29 5 
CCL3L I pseudogene absent 131 7 0 
Total (samples) 149 36 5 
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From the table, the x2 test shows that there is significant relationship 
between CCL3LI pseudogene and the copy number of 
CCL3L 1/CCL4L 1 (p = 0.0008). However, this tested relationship is 
based on all samples having an equal chance of possessing a CCL3L1 
pseudogene independent of copy number. Thus, taking into account 
the copy number of CCL3LI/CCL4LI is necessary to confirm the 
significant relationship between them. 
Table 3.3: The CCL3LI pseudogene from observation, the CCL3L1 
pseudogene from prediction and the copy number of CCL3L I/CCL4L I 
in ECACC (UK) samples. 
Copy number of CCL3L11CCL4L1 1 2 3 4 
Observed CCL3L1 pseudogene 4 14 29 5 
Predicted CCL3LI pseudogene 4 26.7 11.5 2 
Total (samples) 33 116 36 5 
NB. The numbers of predicted GGLJL7 pseuaogene are caicuiatea 
from the probability of samples that will find at least one copy of 
CCL3L 1 pseudogene. 
After taking the copy number of CCL3LI/CCL4LI into account, the x2 
test still shows that there is significant relationship between CCL3L 1 
pseudogene and the copy number of CCL3L 1/CCL4L I (p = 0.0006). 
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Lastly, the mean copy number of CCL3LI/CCL4LI between CCL3L1 
pseudogene present group and CCL3LI pseudogene absent group 
was calculated and tested for significant difference. The results are 
shown in Table 3.4. 
Table 3.4: Mean copy numbers of CCL3L 1/CCL4L 1 in CCL3L1 
pseudogene present group and CCL3LI pseudogene absent group in 
ECACC (UK) samples. 
The presence of Pseudogene present Pseudogene absent 
CCL3LI pseudogene (N=52) (N=140) 
Mean copy number of 2.67 1.81 
CCL3L 1/CCL4L I
The t-test shows that the mean copy numbers of CCL3LI/CCL4LI 
between these two groups are significantly different (p = 4.17 x 10"16). 
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3.3 CEPH HapMap samples 
3.3.1 CCL3LI pseudogene in CEPH HapMap samples 
The CCL3LI pseudogene was also investigated in 90 CEPH HapMap 
samples. The CCL3L1 pseudogene was found in 17 out of 90 samples, 
and in 13 out of 60 samples when children were excluded. 
3.3.2 The relationship between CCL3LI pseudogene and 
CCL3L1/CCL4LI copy number in CEPH HapMap samples 
The relationship between the presence of the CCL3LI pseudogene 
and the copy number of CCL3L 1/CCL4L I in CEPH HapMap samples 
was examined as for the ECACC (UK) samples. Moreover, CEPH 
HapMap samples allowed the investigation of the relationship between 
haplotype copy number of CCL3L I/CCL4L I and the presence of the 
CCL3L I pseudogene, since the haplotype copy number of 
CCL3LI/CCL4LI in these samples can be examined using segregation 
analysis. All results are shown in Tables 3.5-3.8. 
Table 3.5: The presence of CCL3LI pseudogene and the copy number 
of CCL3L1/CCL4LI in CEPH HapMap samples (excluding children). 
Copy number of CCL3L 1/CCL4L 1 01 2 3 
CCL3L 1 pseudogene present 01 6 6 
CCL3L 1 pseudogene absent 2 13 29 3 
Total (samples) 2 14 35 9 
A x2 test shows that there is a significant relationship between CCL3L I 
pseudogene and the copy number of CCL3L 1/CCL4L I (p = 0.0144). 
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Similar to the analysis in ECACC (UK) samples, this tested relationship 
is based on all samples having an equal chance independent of copy 
number. Thus, taking into account the copy number of 
CCL3LI/CCL4LI is necessary for confirming the significant relationship 
between them. 
Table 3.6: The CCL3LI pseudogene from observation, the CCL3LI 
pseudogene from prediction and the copy number of CCL3LIICCL4LI 
in CEPH HapMap samples (excluding children). 
Copy number of CCL3L 1/CCL4L I 1 2 3 
Observed CCL3L I pseudogene 1 6 6 
Predicted CCL3L1 pseudogene 1 4.9 1.8 
Total (samples) 14 35 9 
NO. The numbers of predicted CCL3L7 pseuclogene are calculated 
from the probability of samples that will find at least one copy of 
CCL3L I pseudogene if all repeat units have the same probability. 
From the table, a t-test shows that there is no significant difference in 
CCL3L I/CCL4L i copy number between observation and prediction 
(p = 0.218). 
Nevertheless, the association between the presence of CCL3LI 
pseudogene and the haplotype copy number of CCL3LI/CCL4LI was 
further analyzed, and data are shown in Table 3.7 and Table 3.8, 
respectively. 
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Table 3.7: The presence of CCL3LI pseudogene and the haplotype 
copy number of CCL3LI/CCL4LI in CEPH HapMap samples 
(excluding children). 
Fresence of CCL3LI pseudogene Haplotype copy number of 
CCL3L 1/CCL4L 1 
0 1 2 
CCL3L I pseudogene present 0 9 
Unknown 0 0 
CCL3L I pseudogene absent 24 
g 
7 
Total (haplotypes) 24 60 16 
Table 3.8: The presence of CCL3LI pseudogene and the haplotype 
copy number of CCL3LI/CCL4LI in CEPH HapMap samples 
(excluding children, and grouped for Fisher's exact test). 
Presence of CCL3LI pseudogene Haplotype copy number of 
CCL3L IICCL4L I (total) 
1 (60) 2(16) 
CCL3L I pseudogene present 39 
CCL3L I pseudogene absent 49 7 
A Fisher's exact test shows that there is a significant relationship 
between CCL3LI pseudogene and the haplotype copy number of 
CCL3L I/CCL4L I (p = 3.6 x 10-5) 
A t-test shows that the mean copy numbers of CCL3L I/CCL4L I 
between CCL3LI pseudogene present group and CCL3LI 
pseudogene absent group are significantly different (p = 0.0008). The 
mean copy numbers of CCL3LI/CCL4LI in these two groups are 2.38 
and 1.70, respectively. 
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3.4 YRI HapMap samples 
3.4.1 CCL3Ll pseudogene in YRI HapMap samples 
CCL3LI pseudogene assay was carried out in YRI (African) samples. 
After investigation, the CCL3L I pseudogene was found in 58 out of 90 
samples, and in 37 out of 60 samples when children were excluded. 
3.4.2 The relationship between CCL3LI pseudogene and 
CCL3L1/CCL4LI copy number in YRI HapMap samples 
The investigation of the relationship between the presence of the 
CCL3L 1 pseudogene and the copy number of CCL3L 1/CCL4L I in YRI 
samples was analysed as for CEPH HapMap samples. The data are 
shown in Table 3.9. 
Table 3.9: The presence of CCL3LI pseudogene and the copy number 
of CCL3L I/CCL4L I in YRI samples (excluding children). 
Copy number of 2 3 4 5 6 7 8 9 10 
CCL3L 1/CCL4L I 
1 
CCL3L I pseudogene 3 2 12 8 5 5 1 0 1 
present 
CCL3LIpseudogene 4 8 3 1 4 1 0 2 0 
absent 
Total (samples) 7 10 15 9 9 6 1 2 1 
A x2 test grouping CCL3LI/CCL4LI copy numbers of 2-4,5 and 6-10 
shows that there is no significant relationship between CCL3LI 
pseudogene and the copy number of CCL3LI/CCL4LI (p = 0.6623). 
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A Fisher's exact test showed that there is no significant relationship 
between CCL3L I pseudogene and the haplotype copy number of 
CCL3L IICCL4L 1(p = 0.5884). 
A t-test showed that the mean copy numbers of CCL3LI/CCL4LI 
between CCL3LI pseudogene present group (4.95) and CCL3LI 
pseudogene absent group (4.26) are not significantly different (p = 
0.087). 
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3.5 CHB/JPT HapMap samples 
3.5.1 CCL3LI pseudogene in CHB/JPT HapMap samples 
After CCL3LI pseudogene assay was carried out in CHB/JPT samples, 
the CCL3L I pseudogene was found in 48 out of 90 samples. 
3.5.2 The relationship between CCL3L1 pseudogene and 
CCL3LI/CCL4L1 copy number in CHB/JPT HapMap samples 
Like ECACC (UK) samples, the relationship between CCL3L I 
pseudogene and CCL3LI/CCL4LI copy number was investigated in 
CHB/JPT samples. The data are shown in Table 3.10. 
Table 3.10: The presence of CCL3L1 pseudogene and the copy 
number of CCL3L1/CCL4LI in CHB/JPT samples. 
Copy number of 1 2 3 4 5 6 7 8 
CCL3L 1/CCL4L 1 
CCL3L1pseudogene 0 2 9 12 11 6 5 3 
present 
CCL3LIpseudogene 3 11 8 11 4 5 0 0 
absent 
Total samples 3 13 17 23 15 11 5 3 
A x2 test grouping CCL3LI/CCL4LI copy numbers of 1-3,4-5 and 6-8 
shows that there is no significant relationship between CCL3LI 
pseudogene and the copy number of CCL3LI/CCL4LI (p = 0.2304). 
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The mean copy numbers of CCL3LI/CCL4LI in CCL3LI pseudogene 
present group and CCL3LI pseudogene absent group are 4.77 and 
3.40, respectively. A t-test shows that the mean copy numbers of 
CCL3L 1/CCL4L 1 between these two groups are significantly different 
(p = 2.75 x 10"5). 
In summary, this CCL3LI pseudogene assay showed that the CCL3LI 
pseudogene is found to vary between individuals and in populations, as 
does the copy number of CCL3L 1/CCL4L 1. However, the CCL3L 1 
pseudogene only has a significant association with CCL3LI/CCL4LI 
copy number and haplotype of CCL3LI/CCL4LI copy number in 
ECACC and CEPH HapMap samples. 
To answer the next question in the objectives of this study, the SNP 
and microsatellite assays were carried out to investigate the 
association between single-copy markers, including SNPs flanking the 
region of CCL3L 1/CCL4L 1 and CCL3 microsatellite, and 
CCL3L1/CCL4L1 copy number. In addition, the SNPs within the repeat 
unit of CCL3LI/CCL4LI also were tested for the association with 
CCL3LI/CCL4LI copy number. More details and results are provided 
in the next chapter. 
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Chapter 4: SNP and Microsatellite assays 
4.1 Introduction 
To search for a genetic marker that could be used to determine copy 
number of CCL3L 1/CCL4L 1 and/or to tag the CCL3L 1 pseudogene, an 
easy method for investigation was a direct test of association between 
the CCL3L 1 pseudogene, CCL3L 1/CCL4L 1 copy number and a 
selected single copy genetic marker. 
In this study, the single copy genetic markers used to investigate were 
SNPs and microsatellites since they are widely used to discover genes 
for common and complex diseases, and to investigate association 
between markers and causal alleles. 
4.2 SNP assays 
4.2.1 Introduction 
SNPs are a kind of human variation in which single base pair variation 
is found in > 1% of chromosomes in a given population (Feuk et al. 
2006). They are abundant and can be found throughout the human 
genome both in coding and non-coding DNA. There are, currently, 
several techniques available for genotyping SNPs, from classical 
methods like restriction fragment length polymorphism (RFLP), to the 
high-throughput method such as SNP chips, in which thousands of 
SNPs can be analysed simultaneously in a single microarray. SNPs 
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have been now well accepted and exploited (alone or combined with 
other markers) as a genetic tool in genome wide association studies 
(GWAS) to find variants underlying diseases. Examples include the 
discovery of the association between polymorphism of the complement 
factor H gene (CHF) and age-related macular degeneration (AMD) 
(Klein et aL 2005) and a SNP in a non-coding region creating a 
transcription factor binding site and altering the hepatic expression of 
SORTI gene effected plasma low-density lipoprotein cholesterol (LDL- 
C) and very low-density lipoprotein (VLDL) levels (Musunuru et at 
2010). 
Consequently, SNPs were the markers selected to perform the 
investigation of association among SNPs, CCL3L1/CCL4LI copy 
number and the CCL3LI pseudogene. The investigated SNPs were 
selected from the CCL3 region, inside the CCL3LI/CCL4LI variable 
region and SNPs suggested by linkage disequilibrium analysis. More 
details are described in the materials and methods, in section 2.4. 
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4.2.2 Association between SNPs and CCL3LI/CCL4LI copy 
number 
All investigated SNPs were genotyped by PCR-RFLP techniques, and 
then their alleles were tested for the association with CCL3L 1/CCL4L 1 
copy number using a x2 test (CCL3LI/CCL4LI copy number in ECACC 
samples was determined by Dr. Susan Walker, and CCL3LI/CCL4LI 
copy number in Basque, CEPH HapMap, CHB/JPT and YRI samples 
was determined by Dr. Danielle Carpenter). The results are 
summarized in Tables 4.1 to Table 4.5. 
Briefly, there were five SNPs that showed a strong association with 
CCL3LI/CCL4LI copy number in ECACC samples (p = 0.0001). These 
included rs3744594, rs2277661, which were located inside the 
CCL3L I/CCL4L 1 repeat unit, and rs8064426, rs16972085 and 
rs8070238 which were located in the flanking region and suggested by 
LD analysis. The association between SNPs located inside the 
CCL3L 1/CCL4L 1 repeat unit and CCL3L I/CCL4L 1 copy number were 
also shown to vary significant in the HapMap populations. Lastly, there 
was no significant relationship between a SNP at CCL4LI region and 
CCL3L1/CCL4L1 copy number. 
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Table 4.1: Relationship between SNPs at CCL3 and CCL3LI/CCL4LI 
copy number in 192 ECACC samples. 
SNP Genotype 
CCL3L1/CCL4LI copy number 
(total) p-value 
(total) 0 
(2) 
1 
(33) 
2 
(116) 
3 
(36) 
4 
(5) 
(x2) 
AA (67) 1 18 35 12 1 
rs 1634502 AT (87) 1 10 58 14 4 0.1043 
TT (38) 0 5 23 10 0 
CC (59) 1 13 33 11 1 
rs1634492 CA (88) 1 12 55 16 4 0.7378 
AA (45) 0 8 28 9 0 
rs1130371 CC (120) 2 25 73 18 2 
and CT (64) 0 7 37 17 3 0.0387 
rs1804185* TT (8) 0 1 6 1 0 
GG (25) 1 8 12 4 0 
rs1851503 GT (77) 1 12 48 13 3 0.1738 
TT (90) 0 13 56 19 2 
AA (34) 1 12 16 5 0 
rs9972960 AG (80) 1 13 49 14 3 0.0135 
GG (78) 0 8 51 17 2 
NB. *No polymorphism at rs1804185 in ECACC samples. 
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Table 4.4: Relationship between SNPs suggested from LD analysis 
and CCL3L 1/CCL4L I copy number in ECACC and Basque samples. 
SNP Sample Genotype CCL3LI/CCL4LI copy number Total p-value 
0 1 2 3 4 (x2) 
AA 1 0 3 0 0 4 
rs8064426 ECACC AG 1 21 10 2 2 36 0.0001 
GG 0 12 103 34 3 152 
Total 2 33 116 36 5 192 
AA 2 0 0 1 0 3 
rs8064426 Basque AG 1 23 2 3 0 29 0.0001 
GG 1 7 86 26 2 122 
Total 4 30 88 30 2 154 
AA 2 33 103 20 2 160 
rs16972085 ECACC AG 0 0 10 16 1 27 0.0001 
GG 0 0 0 0 2 2 
Total 2 33 113 36 5 189 
AA 4 29 83 25 1 142 
rs16972085 Basque AG 0 1 5 5 1 12 0.0093 
GG 0 0 0 0 0 0 
Total 4 30 88 30 2 154 
AA 0 0 36 7 0 43 
rs868340 ECACC AT 1 19 54 17 1 92 0.0002 
TT 1 14 23 11 4 53 
Total 2 33 113 35 5 188 
CC 1 20 109 35 5 170 
rs8070238 ECACC CT 1 13 4 1 0 19 0.0001 
TT 0 0 0 0 0 0 
Total 2 33 113 36 5 189 
CC 1 20 78 30 4 133 
rs9910447 ECACC CT 1 10 33 5 1 50 0.0515 
TT 0 3 0 0 0 3 
Total 186 
GG 184 
rs12453313 ECACC GT 
W 
5 0.6489" 
TT 0 
Total 1 1 189 
NB. *usina F isher's exact test 
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Table 4.5: Relationship between SNP rs4796195 at CCL4LI and 
CCL3L 1/CCL4L I copy number in 190 ECACC samples. 
Genotype CCL3L1/CCL4LI copy number (Total) p-value 
(Total) 1 (33) 2 (116) 3 (36) 4 (5) (x2) 
AA (128) 26 79 19 4 
AG (51) 0 33 17 1 0.1133 
GG (11) 7 4 0 0 
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4.2.3 Association between SNPs and CCL3LI pseudogene 
Genotyped SNPs in the investigation of association between SNPs and 
CCL3LI/CCL4LI copy number were also used to examine a 
relationship with the CCL3LI pseudogene. The results are shown in 
Tables 4.6 to Table 4.10. 
In brief, there were two SNPs, rs3744594 (allele A) and rs16972085 
(allele G), which showed a strong relationship with CCL3LI 
pseudogene (p = 0.0001) in ECACC samples. 
Table 4.6: Relationship between SNPs at CCL3 and CCL3L1 
pseudogene in 192 ECACC samples. 
SNP Genotype 
The presence of 
CCL3LI pseudogene p-value 
(total) Present Absent (x2) 
AA (67) 16 51 
rs1634502 AT (87) 22 65 0.3131 
TT (38) 14 24 
CC (59) 13 46 
rs 1634492 CA (88) 25 63 0.5461 
AA (45) 14 31 
rs1130371 and CC (120) 27 93 
rs1804185* CT (64) 22 42 0.0650 
TT (8) 3 5 
GG (25) 5 20 
rs1851503 GT (77) 15 62 0.0459 
TT (90) 32 58 
AA (34) 7 27 
rs9972960 AG (80) 17 63 0.0752 
GG (78) 28 50 
NB. No polymorphism at rs16O4165 in L LJkLU samples. 
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Table 4.9: Relationship between suggested SNPs from LD analysis and CCL3L1 
pseudogene in ECACC samples. 
SNP Genotype CCL3L1 pseudogene Total p-value (x2) 
Present Absent 
AA 1 3 4 
rs8064426 AG 11 25 36 0.6408 
GG 40 112 152 
Total 52 140 192 
AA 31 129 160 
rs16972085 AG 19 8 27 0.0001 
GG 2 0 2 
Total 52 137 189 
AA 7 36 43 
rs868340 AT 25 67 92 0.1002 
TT 19 34 53 
Total 51 137 188 
CC 46 124 170 
rs8070238 CT 6 13 19 0.6756 
TT 0 0 0 
Total 52 137 189 
CC 42 91 133 
rs9910447 CT 9 41 50 0.0439 
TT 0 3 3 
Total 51 135 186 
GG 49 135 184 
rs12453313 GT 2 3 5 0.6129* 
TT 0 0 0 
Total 51 138 189 
NB. *Using Fisher's exact test 
Table 4.10: Relationship between SNP rs4796195 at CCL4LI and CCL3L1 
pseudogene in 190 ECACC samples. 
Genotype The presence of CCL3LI pseudogene p-value (x 2 ) 
(Total) Present Absent 
AA(128) 25 103 
AG (51) 26 25 0.0004 
GG (11) 1 10 
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4.2.4 Tag-SNPs for CCL3LI/CCL4LI copy number 
To discover a SNP that could be used to determine copy number of 
CCL3L 1/CCL4L 1, linkage disequilibrium analysis was performed in 
CEPH HapMap samples using Haploview (Barrett et al. 2005). Two 
SNPs, rs16972085 and rs8064426, were found as shown in Table 
4.11. 
Table 4.11: The relationship between genotype and CCL3L I/CCL4L 1 
copy number and their mean copy number in SNP rs16972085 and 
rs8064426 
SNP Genotype 
1 
CCL3LI/CCL4Li copy 
number 
0123 
Total 
Mean 
copy 
number 
AA 4 24 46 8 82 1.707 
rs16972085 AG 0 02 5 7 2.714 
GG 
Total 
0 
4 
00 
24 48 
0 
13 
0 
89 
0.000 
AA 1 00 0 1 0.000 
rs8064426 AG 0 19 6 2 27 1.370 
GG 3 4 42 12 61 2.032 
Total 4 23 48 14 89 
From the table, based on the mean copy number and the relationship 
between genotype and CCL3LI/CCL4LI copy number, allele G of SNP 
rs16972085 could be used to tag 2 copy haplotypes, and allele A of 
SNP rs8064426 could be used to tag 0 copy haplotypes. 
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To evaluate the potential of these tag-SNPs as markers for the 
determination of CCL3LI/CCL4LI copy number, both SNPs were 
tested for association with CCL3LI/CCL4LI copy number in ECACC 
and Basque samples. 
Apparently, the investigation of their relationship showed that both 
SNPs had strong association with the CCL3LI/CCL4L1 copy number 
(p<0.001) in both ECACC and Basque samples. So, the combination of 
these two promising SNPs was used for prediction of CCL3L 1/CCL4L 1 
copy number in ECACC and Basque samples. The accuracy of 
prediction was investigated by comparison to the known 
CCL3LI/CCL4LI copy number using PRT (the data were kindly 
provided by Dr. Danielle Carpenter); the study in Basque samples was 
undertaken blind to CCL3L 1/CCL4L I copy number. 
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The prediction of CCL3L 1/CCL4L 1 copy number in ECACC and 
Basque samples was carried out using the hypothesis as shown in 
Figure 4.1 and Table 4.12. 
rs16972085 rs8064426 CCL3LI/CCL4LI copy number 
Haplotype A0 
AA 
Haplotype B1 
AG 
Haplotype C2 
GG 
Figure 4.1: The prediction of CCL3LI/CCL4LI copy number 
haplotypes by using a combination SNPs of rs16972085 and 
rs8064426. 
Table 4.12: genotypes of a combination of SNPs for prediction of 
CCL3L 1/CCL4L I copy number. 
rs16972085 
(genotype) 
rs8064426 
(genotype) 
CCL3LI/CCL4LI 
copy number 
AA AA 0 
AA AG 1 
AA GG 2(1/1) 
AG GG 3 
GG GG 4 
AG AG 2 (2/0) 
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4.2.5 Prediction of CCL3LI/CCL4L1 copy number in ECACC and 
Basque samples 
Using a combination of SNPs, rs16972085 and rs8064426, to predict 
the copy number of CCL3L 1/CCL4L 1 in 192 ECACC and 157 Basque 
samples, they were approximately 70% correct (i. e. 72.34% and 
71.43%, respectively). The data of CCL3LI/CCL4L1 copy number 
prediction in ECACC and Basque samples are shown in Appendix. 
4.3 CCL3 microsatellite analysis 
4.3.1 Introduction 
Microsatellites, as genetic markers, are numerous and found 
throughout the human genome. Due to their polymorphic nature, 
microsatellites are generally informative, and as a consequence, their 
analysis has been applied in many fields, as mentioned in the 
introduction 1.3 (Goldstein and Schlötterer 1999). 
Recently, microsatellites were found to be associated with copy 
number variants, and might have a role in the formation of copy 
number variants (Kim et al. 2008). Moreover, when analysis of a 
microsatellite is combined SNP genotyping, it will help to extend SNPs 
and show more detailed LD than the pair of SNPs or microsatellites 
alone (Payseur et al. 2008). Therefore, integration of these two genetic 
markers might help to improve LD of copy number variant in 
duplication-rich regions of the genome which may exist on multiple 
haplotypic backgrounds (Locke et al. 2006). 
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4.3.2 Association between CCL3 microsatellite and the copy 
number of CCL3L 1/CCL4L I
Here the compound microsatellite (CCL3CT) at CCL3 region, which 
was designed by Susan Walker for investigation of the copy number 
variation at CCL3 (Walker 2009), was applied to study the association 
with the copy number of CCL3L1/CCL4L1 in 192 ECACC samples. The 
compound microsatellite (CCL3CT) is composed of CT-rich 
microsatellite with predominant repeat units of CTTT, CCTT, CCCT 
and CT. It is located about 99kb from the location of CCL3L1 and its 
sequence as recorded in the human genome sequence assembly is 
shown in Figure 4.2. 
ACCATGACAACTAGAAGATGGTCTtagcaactccctt(ccct)2cctt(ccct)4(cctt)2t(ct)3 
(cttt)3tt(cttt)6c(cttt)2(ct)3tt(ct)5c(cctt)16(cttt)3etcttccaagacaaggtctcattctgtggcccagg 
ctggagtgcaGTGACTCGATCTTGGCTCAC 
Figure 4.2: The sequence of CCL3CT microsatellite. 
At Chr. 17: 31446870-31447279 [UCSC: Mar. 2006 (NCBI36/HG18)]. 
After the microsatellite amplification products were separated by 
capillary electrophoresis on an A1313100,180 out of 192 ECACC 
samples had two peaks with ratio 1: 1, and 8 out of 192 had one peak. 
Although these eight samples were not investigated further as to 
whether they possess one or two copies of CCL3, this work implies that 
most UK samples have two copies of CCL3, and these samples do not 
show a copy number variation at the CCL3 region. 
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Surprisingly, there were 4 samples that showed more than 2 peaks, 
which were C0896 and C0210 from the ECACC panel 1 and C0164 
and C0990 from the ECACC panel 2. However, after they were re- 
analyzed again using the selected microsatellites, D18S51 and 
D21S11, which were used for individual identification (Kimpton et al. 
1996), the results showed that C0896 and C0210 might have somatic 
mutation (Figure 4.3), and C0164 and C0990 were mixed samples 
(Figure 4.4). 
Excluding these 4 samples, the assay showed there was extensive 
allelic diversity of CCL3CT microsatellite in this region. The 
microsatellite PCR products were found in two ranges, 270bp to 301 bp 
and 341 bp to 464bp, as shown in Figure 4.5. 
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After CCL3CT microsatellite alleles were categorized by their 
associated CCL3L1/CCL4L1 copy number, their allele patterns do not 
differ between the groups. The alleles were still found in two ranges, 
except in samples of zero copy number of CCL3LI/CCL4L1, in which 
alleles were found only within the range of microsatellite PCR products 
between 341 bp and 464bp. However, this observation for zero copy 
number of CCL3LIICCL4LI samples still needs further investigation 
because there are only two samples of zero copy number of 
CCL3L1/CCL4L1 in this study. The data are shown in Figure 4.6. 
200 
180+- 
160 
140 
120 
 0 copies 
ö 100 
80  1 copy 
60 2 copies 
40 
 3 copies 
20 4 copies 
0 
270-301 341-464 
Lengths of CCL3CT microsatellite PCR product 
Figure 4.6: The comparison of CCL3CT microsatellite alleles grouped 
according to the copy number of CCL3LI/CCL4L>. 
Two ranges of CCL3CT microsatellite PCR product lengths are seen, 
270bp to 301 bp and 341 bp to 464bp. 
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To investigate the association between CCL3 microsatellite and the 
copy number of CCL3L I/CCL4L I, CCL3CT microsatellite alleles were 
grouped by the ranges of CCL3CT microsatellite PCR product length 
and the copy number of CCL3LI/CCL4LI. The data are shown in 
Tables 4.13 and 4.14. 
Table 4.13: The number of CCL3CT microsatellite alleles in each 
group of CCL3LIICCL4LI copy number. 
Copy number of 0 1 2 3 4 
CCL3L IICCL4L 1 
Range of CL3CT 
microsatellite alleles 
270-301 0 9 49 19 3 
341-464 4 54 174 49 7 
Table 4.14: The number of CCL3CT microsatellite alleles in each 
group of CCL3LI/CCL4LI copy number (grouped for x2 test). 
Copy number of 0-1 2 3-4 
CCL3L IICCL4L I 
Range of CCL3CT 
microsatellite alleles 
270-301 9 49 22 
341-464 58 174 56 
94 
However, after the association was tested using Chi-square analysis, 
the results showed that there is no significant relationship between 
CCL3CT microsatellite alleles and CCL3L 1/CCL4L I copy number (p = 
0.0982) (n=188). 
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4.3.3 Association between CCL3 microsatellite and CCL3L9 
pseudogene 
In addition, the association between CCL3 microsatellite genotype and 
CCL3L 1 pseudogene (presence/absence) was also examined in 188 
ECACC samples. The CCL3CT microsatellite alleles were categorized 
into two groups, according to the presence of CCL3LI pseudogene 
group and the absence of CCL3L1 pseudogene group. The results 
showed that the patterns of microsatellite alleles do not differ between 
the groups, and they were found in two ranges, 270bp to 301 bp and 
341 bp to 464bp, the same as that was found in the study of the 
association between CCL3 microsatellite and CCL3L1/CCL4L1 copy 
number. The data are shown in Figure 4.7 and Table 4.15. 
250 
200 
150 
100 
50 
0 
Ll 
  
Pseudogene present 
  
Pseudogene absent 
270-301 341-464 
Length of CCL3CT microsatellite PCR product 
Figure 4.7: The comparison of CCL3CT microsatellite alleles grouped 
according to the presence of pseudogene. 
Two ranges of CCL3CT microsatellite PCR product lengths are seen, 
270bp to 301 bp and 341 bp to 464bp. 
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Table 4.15: The number of CCL3CT microsatellite alleles in each 
group of CCL3LI pseudogene. 
A x2 shows that there is a significant relationship between CCL3CT 
microsatellite alleles and CCL3L I pseudogene (p = 0.0277). 
To summarize, CCL3CT microsatellite has not found to have a 
relationship with the copy number of CCL3L1/CCL4LI, but it shows a 
weak association with CCL3LI pseudogene. However, this might 
suggest that the CCL3CT microsatellite has a high rate of mutation, the 
CCL3L IICCL4L I CNV has a high rate of mutation, and/or there has 
been high recombination at the CCL3LI and CCL4LI region. 
As the association between SNPs, microsatellites and 
CCL3LI/CCL4LI copy number were not found, there is no one marker 
that can be used to predict the CCL3LI/CCL4L1 copy number. One 
plausible hypothesis is that CCL3LI/CCL4L1 copy numbers might have 
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different haplotype backgrounds. As a result, the relationship between 
single-copy markers and CCL3LI/CCL4LI will be reduced. Therefore, 
to overcome this, the hapiotype of CCL3L 1/CCL4L 1 was identified and 
tested for association with CCL3L 1/CCL4L 1 copy number again using 
LD analysis. Moreover, the defined haplotypes of CCL3L 1/CCL4L 1 
were also analysed for evolutionary history of variation in this region by 
comparison to chimpanzee. More details and results are shown in the 
next chapter. 
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Chapter 5: Linkage disequilibrium and haplotype 
block analysis at CCL3LI and CCL4LI 
5.1 Introduction 
Since LD was characterized in the human genome (Reich et al. 2001), 
and the International HapMap Project provided an invaluable human 
variant resource (The International HapMap Consortium 2005,2007; 
The International HapMap 3 Consortium 2010), LD has been a 
powerful genetic tool to investigate direct and indirect gene-disease 
mapping, especially in genome wide association studies (GWAS) as 
mentioned in the introduction. As a result, LD was also exploited as a 
tool to search for a tag-SNP which can be used to determine 
CCL3L 1/CCL4L I copy number. 
In this first approach, studies of association between SNPs, 
microsatellites and CCL3L I/CCL4L I copy number, did not provide 
satisfactory results. So, LD was applied to find a tag-SNP for 
determination of CCL3LI/CCL4LI copy number using CEPH-HapMap 
samples. 
Unfortunately, although suggested tag-SNP from LD analysis provided 
significant associations in ECACC and Basque samples, using them to 
determine CCL3LI/CCL4LI copy number in these samples was only 
70% concordant. A new method, therefore, was needed to improve this 
association study. 
99 
Promisingly, haplotype-based tests of association were introduced that 
might be able to improve the association study, since it could provide 
greater power than using single genetic markers (Clark 2004; de 
Bakker at al. 2005). Furthermore, haplotype-based tests of association 
have been successful in gene mapping, such as at the APOE locus in 
Alzheimer's disease (Fallin et at 2001), the P-selectin gene and 
myocardial infarction (Tregouet at al. 2002), and the Renin- 
angiotensin-aldosterone system genes and hypertension (Niu at at 
2009). 
Therefore, sequence haplotype-based tests were applied to further 
investigate a SNP or a haplotype block, which showed a strong 
association with CCL3LIICCL4LI copy number haplotypes, in the 
CEPH-HapMap samples using LD. 
The application of phased haplotypes and thus LD in this association 
study should not only provide SNPs which could be used to determine 
the CCL3LI/CCL4LI copy number haplotype, but it also could provide 
evidence of the genomic evolution of CCL3L 9/CCL4L I segment as 
illustrated in Figure 5.1. 
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Ancestral 
G 
G1 Copy haplotype 
1 Copy haplotype 
1 Generations 
Generations 
A1 Copy haplotype 
rý 1 ". ý. ý +-E: ýJý Modern 
G1 Copy haplotype AI Copy haplotype A2 Copy haplotype 
Figure 5.1: Testing the association between hypothetical SNPs and 
CCL3L1/CCL4LI haplotypes on the basis of linkage disequilibrium 
(LD). The boxes represent to copy number haplotype, and "A" and "G" 
are SNPs. If the association between SNPs and CCL3LIICCL4LI 
haplotype was not confounded by recombination or recurrent mutation 
of CCL3L 1/CCL4L 1 haplotype, and/or reverse mutation of 
CCL3L 1/CCL4L 1 haplotype, the study would show the relationship 
between SNPs and CCL3L 1/CCL4L 1 haplotypes when the SNPs were 
typed and tested for association with CCL3L1/CCL4LI haplotypes. As 
illustrated in Figure 5.1 suppose base G was the ancestral state and 
was associated with a1 copy haplotype. After many generations, a 
SNP was created, and the base G in one lineage was changed to base 
A. Again, after further generations, the CNV occurred. SNP genotyping 
would show a relationship with CNV as in the figure; base G would 
correlate with 1 copy haplotype, and base A would be associated with 
2 copy haplotype. 
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So, by identify tag-SNPs to determine CCL3LI/CCL4LI haplotypes, 
the evolution of CCL3L I/CCL4L I haplotypes could be identified as 
well. 
To generate the CCL3L1 and CCL4L1 sequence haplotypes in CEPH 
HapMap samples, however, several techniques were necessary; 
sequencing, segregation analysis, allele-specific PCR and emulsion- 
fusion PCR because sequencing alone cannot identify the 
CCL3L 1/CCL4L I sequence haplotype in some samples. For example, 
for samples which have two or more copies of CCL3L1/CCL4LI, 
sequencing cannot provide the information of which variant bases 
occur together as a haplotype. Therefore, the samples also needed 
segregation analysis and/or allele-specific PCR to establish the 
CCL3L1/CCL4LI haplotype. Lastly, some samples also required 
emulsion-fusion PCR to combine both CCL3L1 and CCL4L1 
haplotypes together to generate complete haplotypes. 
5.2 Sequence analysis at CCL3L1 and CCL4L1 
5.2.1 Introduction 
CCL3LI and CCL4LI sequencing was performed for the both genes in 
90 CEPH HapMap samples, to identify the sequence variants in both 
loci. The primers and conditions for CCL3L I and CCL4L 1 PCR 
amplification and sequencing are shown in Tables 2.3-2.5 in section 
2.2.4. 
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5.2.2 CCL3L1 sequencing 
CCL3L1 is a copy number variable gene which is paralogous to CCL3, 
and it has a partial repeat, usually called the CCL3L 1 pseudogene. 
Therefore, to read the sequence of CCL3LI, the CCL3L1 PCR 
amplification primers were especially designed to be specific to 
CCL3L1 to avoid co-amplification with CCL3 or CCL3L I pseudogene, 
and they were also designed to avoid common variants themselves. 
To complete the whole sequence of CCL3L1 (about 1.9kb in size), a 
2.1 kb PCR product of CCL3L 1 was used for sequencing. However, the 
length of these CCL3LI PCR products was too long for a single 
sequencing reaction. Thus, nested primers were also designed (to use 
in sequencing PCR) to obtain full length sequence of CCL3LI. The 
CCL3L1 sequencing assay and sequence variant bases are shown in 
Figure 5.2. 
14kb 100kb 100kb 14kb 
CCL3 CCL4 CCL3LI CCL4LI CCL3L 1 CCL4L 1 
17g12 
II CCL3L 1 
2.1 kb pseudogene 
CCL3L1 F1 CCL3L1 F2 CCL3L1 F3 CCL3L1 F4 
17g12 - 
ý-- 
rs2944 rs2277661 rs1804185 rs1828283 CCL3L1R 
rsl7850251 rs2073462 
Figure 5.2: The CCL3LI sequencing assay and discovered sequence 
variant bases at CCL3L1 (Chr. 17: 31546177-31548296 and 31647751- 
31649870). For simplicity, one repeat unit is shown. 
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Sequencing identified 7 common variant bases, and 6 out of 7 were 
validated in the SNP database (dbSNP129). The positions of the 
common sequence variant base are described in section 5.6. 
5.2.3 CCL4LI sequencing 
CCL4L1 sequencing was performed similarly to CCL3L1 sequencing. 
The CCL4LI PCR amplification primers were specifically designed for 
CCL4L1, to avoid co-amplification with the paralogous CCL4, and 
CCL4L1. PCR products for sequencing were produced (about 2.5kb) to 
cover the whole gene sequence (about 1.8kb). The CCL4LI 
sequencing assay and sequence variant bases are shown in Figure 
5.3. 
14kb 100kb 100kb 14kb 
CCL3 CCL4 CCL3LI CCL4LI CCL3LI CCL4LI 
17q12 IN IS ON IN CCL3L 1 2.5kb 
pseudogene 
CCL4L1 F1 CCL4L1F2 CCL4LIF3 CCL4L1F4 CCL4LIF5 rs1810140 
17q12 -i 
Au AL ALAL AL AL ALAL AL 4- 
rs4796195 rs3744594 CCL4LIR 
rs4796194 rs3744595 rs2277660 
rs4796193 rs56184815 rs56363716 
rs3744597 rs56064808 
Figure 5.3: The CCL4LI sequencing assay and discovered sequence 
variant bases at CCL4L1 (Chr. 17: 31663731-31666272). 
The CCL4L1 sequencing identified 13 common variant bases, and 11 
out of 13 were validated in the SNP database (dbSNP129). The 
positions of the common sequence variant bases are described in 
section 5.6. 
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5.3 Segregation analysis 
Segregation analysis was performed to determine the copy number of 
CCL3LI/CCL4L1 per chromosome, and it was also used to confirm the 
copy number of CCL3L 1/CCL4L I typed by the PRT technique. The 
data on CCL3LI/CCL4LI copy number inheritance transmission in 
CEPH-HapMap used in this study were carried out and kindly provided 
by Dr. Danielle Carpenter. In brief, the CCL3L I/CCL4L I copy number 
inheritance transmission patterns were inferred by segregation of 
microsatellites within the copy variable region as described in Walker 
(2009). 
However, there were some CEPH-HapMap families in which 
microsatellite segregation analysis could not provide the information of 
their CCL3L 1/CCL4L I copy number inheritance transmission pattern. 
Fortunately, some of these CEPH-HapMap families were the same as 
reference families from the Centre d'Etude du Polymorphisme Humain 
(CEPH), which can be investigated more closely using markers from 
the CEPH database. Thus, to deduce unambiguously the 
CCL3LIICCL4LI copy number haplotypes in these families, more 
samples from these CEPH families were selected to type their 
CCL3LI/CCL4L1 copy number and to do segregation analysis. This 
segregation analysis was carried out using three selected flanking 
markers from the CEPH database; they were AFM179xg11 / (AC)n, 
UT752 / pcr(n) and Mfdl5-2 / (AC)25. These three markers were 
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located flanking the region of CCL3LI/CCL4LI on Chr. 17: 28313925- 
28314303,30890413-30890839 and 34405617-34405867, 
respectively. CCL3LIICCL41 is located at Chr. 17: 31546382- 
31665958. An example is CEPH-HapMap family 1341 in which the 
CCL3LI/CCL4LI copy number inheritance pattern in the maternal line 
cannot be determined by segregation since all members, including the 
grandfather, grandmother and mother, have 2 copies of 
CCL3L1/CCL4L1, and all have the same pattern of microsatellite 
length. Therefore, the chromosome copy number of CCL3LI/CCL4LI 
in these trios could be either 2/0 or 1/1. Consequently, more children 
were selected to type their CCL3L 1/CCL4L I copy number as shown in 
Figure 5.4. 
11 F---1 12 
1 copy 3 copies 
(1,0) (1,2) 
1 copy 
(1,0) 
14 F--1 13 
2 copies 12 copies 
2 copies 
1 copy 1 cý 2 copies Y pY 
U 
2 copies 2 copies 
Figure 5.4: The pedigree of CEPH family 1341 and their 
CCL3L 1/CCL4L I copy number. 
The numbers 11,12,1,13,14 and 2 in this pedigree are NA07034, 
NA07055, NA07048, NA06993, NA06985 and NA06991 in CEPH- 
HapMap samples, respectively. The numbers in the bracket are 
chromosomal copy numbers of CCL3L1/CCL4L1. 
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The children selected to be typed for CCL3LI/CCL4LI copy number 
were children who showed different pattern of segregation, and their 
patterns of transmission inheritance do not change between the three 
flanking markers. The information provided by the three markers 
indicated that this DNA segment defined by these markers had been 
transmitted as a whole, with no evidence for recombination. The 
pedigree of this family and their genotypes for the three markers are 
shown in Figures 5.5 to Figure 5.7. 
6,6 6,6 1,6 1,6 1,6 1,1 8,6 1,6 
Figure 5.5: CEPH family 1341 and their AFM179xg11 / (AC)n genotypes. 
3,3 3,5 3.4 3,4 9,4 2,4 3,5 3,4 
Figure 5.6: CEPH family 1341 and their UT752 / pcr(n) genotypes. 
1,4 1,4 S, 4 S, 4 3,4 8,5 1,4 3,4 
Figure 5.7: CEPH family 1341 and their Mfd15-2 / (AC)25 genotypes. 
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To summarize, after more children were typed for CCL3LI/CCL4LI 
copy number, the segregation patterns were examined in three 
selected markers and inferred that all grandfather, grandmother and 
mother have chromosome copy number as 1/1. This is because if 
mother (number 2 in the Figure 5.4) has the chromosome copy number 
as 2/0, her children should have the characteristics as follows, 
" 
Based on segregation in these 3 markers, child number 8 should 
have 3 or 1 copies of CCL3L I/CCL4L 1 copy number and 
children numbers 3 and 4 should have 2 or 0 copy of 
CCL3LI/CCL4LI copy number. 
" Based on segregation in markers UT752 / pcr(n) and Mfd15-2 / 
(AC)25, children numbers 5 and 6 should have 3 or 1 copies of 
CCL3LI/CCL4LI copy number. 
However, the CCL3LI/CCL4LI copy number was found 1,1,2,2 and 
2 in children numbers 3,4,5,6 and 8, respectively. So, apparently, this 
mother (number 2 in the Figure 5.4) should have the chromosome copy 
number 1/1, and this implies that her parents should have the 
chromosome copy number 1/1, as well. In addition, the 
CCL3LI/CCL4LI copy number and its inheritance pattern were 
confirmed by the repetition of the results in the pairs of children, 
numbers 3 and 4 and 5 and 6. 
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5.4 Allele-specific PCR assays 
An allele-specific PCR technique was applied to help deduce CCL3L1 
and CCL4LI haplotypes in CEPH-HapMap samples whose haplotypes 
could not be inferred by segregation analysis. 
An example is CEPH-HapMap family 1334, which comprises father 
(NA12146), child (NA10847) and mother (NA12239). Using PRT, these 
individuals possess 3,2 and 1 copies of CCL3LI respectively, as 
shown in Table 5.1. Based on segregation analysis, the CCL3L 1 
haplotypes of mother and child can be established. Since the mother 
possesses I copy, the transmission of this haplotype to the child allows 
the retrospective identification of which haplotype is transmitted from 
father. Further dissection of the father's 2 other copies of CCL3L 1 into 
a haplotype is difficult. From sequencing alone it is not known which 
variant bases at positions 7837,8282,8382 and 9613 occur together 
as CCL3LI haplotypes. Consequently, allele specific PCR assays were 
applied to deduce the CCL3LI haplotypes in this sample. After 
amplification with allele specific primer at position 7837, the allele 
specific PCR products were sequenced to reveal the variant bases on 
the same haplotype as the discriminatory base used in the allele 
specific primers. The sequencing results of allele specific PCR 
products of this sample are shown in Figures 5.8 and 5.9, and the 
CCL3L I haplotypes of this sample are shown in Table 5.2. 
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As is the case for NA12146, additional CEPH HapMap samples whose 
CCL3L 1/CCL4L I haplotypes could not be identified by segregation 
analysis were examined using their allele specific PCR assays. Primers 
are shown in section 2.5. A combination of allele-specific PCRs was 
used to provide complete coverage of CCL3L I and CCL4L 1. 
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5.5 Emulsion haplotype fusion PCR 
Emulsion-fusion PCR was used to make a condensed haplotype of 
sequence variants in CCL3L I with sequence variants in CCL4L I from 
the same repeat unit in CEPH-HapMap samples whose phase 
haplotypes of CCL3L I/CCL4L I could not be inferred by segregation 
analysis alone. This included examples that possess two-copy 
haplotypes of CCL3L I/CCL4L 1. 
An example is CEPH-HapMap family 1408, which comprises father 
(NA12155), child (NA10831) and mother (NA12156). Using PRT, these 
individuals possess 2,3 and I copies of CCL3L 1/CCL4L I respectively. 
Based on segregation analysis, the transmission pattern of 
CCL3L 1/CCL4L 1 copy number in this family is shown in Table 5.3. In 
this family, transmission of the 2-copy CCL3L1/CCL4LI haplotype from 
father to child is ambiguous. The combination of sequence variants in 
CCL3L I that go together with sequence variants in the neighbouring 
copy of CCL4L 1 in each of the two repeats cannot be determined by 
segregation analysis alone. As a result, emulsion-fusion PCR was used 
to combine the haplotype of CCL3L 1 and CCL4L 1, and then the 
CCL3L 1/CCL4L 1 variant combinations in each repeat unit were 
revealed using allele-specific PCR as shown in Figure 5.10 and Table 
5.4. 
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5.6 CEPH HapMap haplotypes at CCL3LI and CCL4L1 
After using several techniques to identify the CCL3LI/CCL4L9 
haplotypes in CEPH-HapMap samples, their copy number haplotypes 
and frequency can be deduced as in Table 5.5 and 5.6. 
Overall, there were found 11 and 10 different sequences in 1- and 2- 
copy number CCL3LIICCL4LI haplotypes, respectively. However, 
there were only 3 different major CCL3L 1/CCL4L 1 haplotypes (as 
indicated in colours in the tables), and it seems that 2-copy number 
CCL3LI/CCL4L1 haplotypes were a combination and duplication of 1- 
copy number CCL3L 1/CCL4L 1 haplotypes. Moreover, evidence of 
recombination between CCL3LI/CCL4LI was also found in 2-copy 
number haplotypes (i. e. 2B6Hybrid, 2C2Hybrid, 2CM1Hybrid1 and 
2CM2Hybrid2 haplotypes). These 2-copy number haplotypes 
consisted of CCL3LI haplotype type 1B and CCL4LI haplotype type 
IA on the same chromosome as shown in Figure 5.11 and Table 5.6. 
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a) 1-copy number CCL3LI/CCL4LI haplotypes 
CCL3L1 CCL4LI CCL3LI CCL4LI CCL3LI CCL4LI 
__ 
I- 
M 
0- 
Type 1A Type 1B Type 1C 
b) 2-copy number haplotypes in which the recombinations occurred 
i) CCL3LI CCL4LI CCL3LI CCL4LI 
or 
CCL3L1 CCL4LI 
2B6 Hybrid haplotype 
m f- 
CCL3L I CCL4LI CCL3LI CCL4LI 
II) 
or 
2C2 Hybrid haplotype 
CCL3LI CCL4LI 
2CM1 Hybrids haplotype 
2CM2 Hybrid2 haplotype 
Figure 5.11: The evidence of recombination between CCL3LI/CCL4LI in CEPH- 
HapMap samples, 
a) shows the 3 major haplotypes in 1-copy CCL3LI/CCL4LI haplotypes (type IA, 1B 
and 1 C). b) shows evidence of recombination which were found in 2-copy 
CCL3L I/CCL4L I haplotypes. i) 2B6 Hybrid haplotype consisted of CCL4L> of type 
1A and CCL3LI of type 1B on the same chromosome. ii) The same as 266 Hybrid 
haplotype, CCL4LI of type 1A was also found with CCL3LI of type 1B on the same 
chromosome in 2C2Hybrid, 2CMlHybridl and 2CM2Hybrid2 haplotypes. 
120 
Cl) N 
n 
0 
Q 
m 
J 
tr 
U 
I 
n 
8 
vi 
ca 
öý Qý ö ö ö ö 
ö 
- 
ö 
h 
ö 
N 
ö 
O) 
O) ö 
cl p 
0 
o 
0- 
Of 
0 
O 
r 
(0 
N 
I- f 
- - 
Lo O r c o 
2 Cp M N N CV CO - (D 'i 
N 
l0 
Q Q a Q 
I- 
L' 
04 
0) 
cý V V (ý Cý U C7 Cý C7 C7 0 
Ü 
V 
Go 
iA 
Zý 
c°'ý Q Q Q Q Q U` a QQ 
Q_ 
w l 
- 
r 
C9 C9 C9 C9 C9 U C9 C9 C9 C9 Ü 
lo 
L' ä (7 C7 C9 C9 C9 U C9 C9 C9 
IC9 
CD 
co 
so 
In 
p) 
LC) v Q Q U U Q Q Q Q QQ 
tC 
U Ö 
J 
J 
Ü 
a 
OD F- F- F- I- F- F- I- F- 
r 
J- 1- 
V 
C 
WN 
NJ 
p 
M 
e 
r 
r 0 0 0 CD 0 0 ii 0 0 9 Ü 
ÖG 
y C 
N 
E2 
v 
< U U 
U U U U U U U ', U 
Cl) 
CD 10 3 äa ch 
0 
0 Q Q Q (9 0 0 C7 U` U' Io 
v aj 
N 
U' C9 C7 U U U UI U ý 
E -- --- 
N 
0) C-4 
co 00 E2 
1 
U U U º- F- 1- 
1 
f U I- I- f- J 
Ü 
N 
a Q Q C9 
? 
CD 
L, 
co 
a 
U o o (D U U U 
F 
U U U 
U 
&0 Lr) 
co F- f U F F- I- 
U U 
N 
Cl) 12 CIO 
U ý 
Q Q Q ¢ 
IQ 
a Q a Q 
04 cli 00 
cý cý cý d a a a ¢ 
--7 
ti 
'e) H F- H 
d) 
N 
m 
M ý U) , 1 UI 
NI 
U 
CL 0o m 
ö 
Z 
N 
N 
col 
co 
c) 
r 
U 
vj v 
m- 
c4 
Ir" 
vi 
a) 
a Z0 
a. 
J U 
M 
J 
U 
E 
c 
n. 0 U 
N 
t0 
F- 
M M C, 
ä 
Po 
C 
y 
CV 
M 
M 
p. p p cD 
N 
O 
CO 
r7 
! 
- 
f Q 1- 1- a 1- I- h 
J 
I 
V " N Q a a a as a Q Q 
w 
ý(p ~r 
V 
r 
V 
U '^ V 
ý ý.. ý U 
M rý a a a U aa Q Q 
tu n 
N 
.-, o C7 (ý (ý t7 C7 0 C7 C7 Jp r 
. 
- V U I- UU U U U 
wý 
ýv 
- 
e eh ai 
Ch ö ° 0 (D (9 a 0 
!'ä 
a 0 0 
N U U U Ci U Cý Cý U U 
ýE 
ýý y rn IN F F F_ F- IU U F- F 
rw N 
CO (Z F- i- F- F- U U F- F" 
= 
n 
M 
ý V V V V 
C. J Cý V Ü U 
/0 (N cD 
? so n V U U U U U U U U U 
O 
Ln f- h- F- U h- U º- U U 
e Co 
J ' m 
Q Q aI U' d < C7 a C7 a 12 lý Co 
a a a Cý Q a (9 ¢ 0 Q 
11 CO r 
F- H H F- h- ! - F- F- F- 
F- 
ß 
c0 
m 
l 
cD 
ml 
c0 
m? 
N 
21 
cý 
mi 
r 
UI = 
ýI 
U 
ý 
m 
yN ý 
C7 
(Z C 
t 
C 
0 
o 
(p 
N I 
Zy Co 
S N N 
N N 
N 
N 
M 
N 
a) 
c 
0 
U 
N 
u) Q 
T 
0 
Q 
(0 
_I_- 
-. 
1 
U 
U 
M 
U 
U 
CD 
E 
c 
a- 0 U 
N 
tD 
N 
CL 
0 
0 
a l0 
J 
J 
U 
U 
J 
J 
U 
U 
a E 
a 
0 U 
N 
0 
N t'1 ý 
5.7Tag-SNP and haplotype block analysis at CCL3LI/CCL4LI 
To search for a SNP or a haplotype block which could show strong 
association with CCL3LI/CCL4L9 haplotypes as defined by full 
sequencing, 1,250 SNPs flanking the CCL3LI/CCL4LI region (nearly 3 
Mb) from the HapMap database were identified by using Haploview. 
After the association between SNPs and CCL3L 1/CCL4L I sequence 
haplotypes was tested, both in terms of copy number haplotypes and 
sub-group of copy number haplotypes divided by their similarity (i. e. as 
indicated in Table 5.5 of section 5.6), the results showed that there 
were no SNPs with a strong association with CCL3LI/CCL4LI 
sequence haplotypes. The results are shown in Tables 5.7 and 5.8. 
Table 5.7: The best SNPs which were associated with 
CCL3L 1/CCL4L I haplotypes. 
Copy number 
haplotype 
D' LOD 1*7 NCBI B36 assembly 
(dbSNP b126) 
SNP Position 
0 85.8 2.70 0.100 rs2287352 32679407 
1 55.9 2.50 0.110 rs1266180 32521381 
2 48.1 2.11 0.141 rs8067329 30864441 
Note: D' and rl are the two most common measures for LD. Both of 
them are in the ranges between 0 and I which D' and ºZ =1 will be 
perfect LD, and indicates that there is no recombination between the 
two loci of SNPs. LOD stands for log odds which displays to the 
statistical significance of LD between a pair of SNPs. The SNP which 
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shows the highest score of D', LOD and r2 with CCL3L I/CCL4L I copy 
number haplotype are represented in the table, but the ? is a more 
useful measure than D' 
Table 5.8: The best SNPs which were associated with 
CCL3L 1/CCL4L I haplotype (analysis in terms of sub-group of copy 
number haplotypes). 
Copy number D' LOD NCBI B36 assembly 
haplotype (dbSNP b126) 
SNP Position 
1A 64.5 1.77 0.201 rs2291189 30616734 
100 2.39 0.091 rs321597 30911907 
IB 45.4 3.13 0.142 rs916841 31501593 
ic 100 3.04 0.490 rs17138323 32043413 
100 3.04 0.490 rs8081787 31937223 
2A 100 1.97 0.165 rs854632 31398892 
49.0 1.22 0.240 rs7218876 32096773 
2B 100 1.45 0.242 rs8071957 32608804 
2C 100 1.78 0.060 rs854658 31376779 
Note: D' and rl are the two most common measures for LD. Both of 
them are in the ranges between 0 and I which D' and r2 =I will be 
perfect LD, and indicates that there is no recombination between the 
two loci of SNPs. LOD stands for log odds which displays to the 
statistical significance of LD between a pair of SNPs. The SNP which 
shows the highest score of D', LOD and rz with CCL3L I/CCL4L I copy 
number haplotype are represented in the table, but the r2 is a more 
useful measure than D'. 
125 
5.8 Evolution of haplotypes at CCL3LI/CCL4LI 
In order to study evolution of human variation, comparison of human 
patterns to closely related species is required because the comparison 
will provide evolutionary information to assess uniqueness in humans 
(Ruvolo 1997; Tung et al. 2010). 
Based on the phylogeny of the hominoid primates it has been 
suggested that chimpanzee is the closest relative organism to human, 
and orang-utan is the most diverged of the great apes (Sibley and 
Ahlquist 1984,1987; Chen and Li 2001). Therefore, to infer an 
ancestral state of CCL3LI/CCL4LI haplotypes in human, the 
CCL3L1/CCL4LI haplotypes in human were compared to 
CCL3L 1/CCL4L I sequence haplotypes in chimpanzee and orang-utan. 
To generate the CCL3LI/CCL4LI haplotype of chimpanzee and orang- 
utan, the whole gene sequence of CCL3L 1/CCL4L 1 in these primates 
was searched using two browsers, including NCBI browser 
(http: //www. ncbi. nim. nih. gov/) and Ensembl browser 
(http: /twww. ensembl. org/), and chimpanzee CCL3L 1/CCL4L I 
sequence haplotype was also derived by using the ancestral state of 
SNPs (the dbSNPI29) from UCSC genome browser 
(httg: //genome. ucsc. edu/). The list of sequence assembly and location 
are shown in the Table 5.9. 
126 
G) 
C 
E 
U 
C 
C 
C 
0 
C 
N 
C 
C) 
C" 
J 
U U 
C 0 
V C 
cv 
E 
9 N 
U, 
d 
72 
A F 
fY 
CW) 
v 
0) 
N Ö 
E 
C 
O 
-lC C 
(D 
d 
qq 
CC') 
00CO ) 
C-4 
0 
m 
E 
C 
O 
. C 
co 
N 
it) 
(0 
00 (0 
C-4 
0 
. 
12 
E 
C 
Ö 
Y 
C 
co 
a 
La 
(0 
00 (0 
CN 0 
J, E 
C 
Ö 
. C 
ca 
N 
Lo 
(0 
000 
C-4 Ö 
E 
C 
Ö 
. C 
co 
a 
C, 4
(0 
N 
Ö 
J40 E 
C 
0 
ad 
C 
04 
(0 
N 
Ö 
E 
C 
Ö 
X. C 
GO 
N 
(D 
C, 4 
(O 
N 
Ö 
E 
C 
Ö 
. C 
C) 
00 
N 
NN 
Ö 
E 
C 
Ö 
Y 
C 
G) 
P- 
ti 
N 
N 
E 
C 
2 
Y 
C 
N 
N 
C 
Oý 
C 
~ 
0 
OM 
0 
M 
_M 
O 
r- 
C) 
04 ý ? 
CY) 
V- 
v 
C14 11 
N 
CY) 
M 
0) 
N 
CIO C4 9 r- j 0 
9 
_01 
ß N M h !ý M 
I 
L6 
ýR 
r r Go CM 
8 
0 .0 
, M 
- 
oMD 
tt 
3 
d' 
(Cp 
m 
CO 
, 
9 
fl- 
M 
O ýp 
M 
OD 
M 
O 
Ö 
C 
C 
C 
N 
N 
ß 
C 
l`0 
ýj 
P. 
I- O) 
IT CN') M 
Oý 
' 
N 
ý 
M 
M fp pp 2 
MN 
r r 
I- f- 1-ý h 
r r 
1 
r 
I_ 
r 
f- 
r ' 
tO 
r co '- ý- 
r 
0 
r 
0 
r 
C 
0 
r ýC 
0 
.C 
U 
t 
U 
L 
U L U 
t 
U 
: L 
U 
L F- U 
"- 
LF 0 
"- 
L 
U U 
ý 
C-4 
O -I Ö oi Ö O O N CV N Nv, ý N 0 ti 00 
O 
N 
O 
N 
_ NI NI NI N NI 
. 
'p . . 
V79 S. 
's 715p. 
C, 
ý 
C. 
V 
2 
r 
2 
r 
a 
N 
m 
N 
cu 
d 
ca 
0 
to ä 
N 
ß 
> 
O O 
cNi 
) 
ý ä ý ä ý 
>.. 
>. T 
ä " ä CI CI 
C 
ä 
CI 
ä a 
> 
_ 
z U 
_ 
z U (L 
ä ä ä (L a a 
d J 
Cl) 
J 
V Ü 
J 
C') Ü 
J 
Ü 
J 
v Ü 
J 
M Ü 
J 
If Ü 
J 
.. Ü 
J 
J 
U 
J 
Cl) 
U 
"ý M. 
J 
U Ü Ü Ü Ü 
U U U U U U U U U 
U U U U U 
m ) aa i ä Co as 90 o co co 
ca cv co o 
. .. N S, 
ö 
ö, 
ö 
ä, 
ö 
°v, 
ö 
öý 
ö 
".. 
m m 
`c° 
o 
o, 
° 
cPL 
c ä c ä 
a a a a a a a a a a a 
p 0 0 0 0 0 0 0 0 0 0 S 
70 
E 
70 
$ 
C 
: 
ý 
` z z z z z z z z 
z z w w W w 
r- N 
T- 
Unfortunately, the UCSC genome browser did not provide the 
CCL3L1/CCL4L1 in orang-utan, and the haplotype information given 
for chimpanzee and orang-utan obtained from NCBI and Ensembi 
browsers were identified as CCL3 and CCL4 when the sequences 
were aligned and inspected for characteristic positions. Therefore, 
finally, CCL3L1/CCL4LI haptotypes in human were compared to 
CCL3L 1/CCL4L 1 haplotypes in chimpanzee by using the data from 
UCSC database only, and the CCL3L1/CCL4L1 haplotypes of 
chimpanzee are shown in Table 5.10. 
After the CCL3L I/CCL4L I haplotypes in human were compared to 
chimpanzee, the results showed that the majority of CCL3L1/CCL4LI 
haplotypes (about 70%) which were found in human were the same as 
found in chimpanzee, i. e. the ancestral state (Table 5.10). 
Regarding the human CCL3LI/CCL4L1 haplotypes, the haplotypes 
might be divided by the location according to the UCSC browser of 
CCL3L1/CCL4L1 repeat unit into two types. The first type was the 
major group including IB and 1C haplotype groups; these haplotypes 
can be found at Chr17: 31647837-31649613 for CCL3L 1 and 
Chr. 17: 31663762-31665561 for CCL4L1 (Table 5.10). The second type 
was IA haplotype group which CCL3LI can be found at Chr17: 
31546263-31548039, and CCL4LI at Chr. 17: 31562196-31563995 
(Table 5.11). 
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Collectively, CCL3L1/CCL4LI haplotypes in human might be 
represented as an evolutionary tree as Figure 5.12. 
rs4(C), rs5(C), rs6(G), 4359'(C) and 3762'(A) 
1B 1 
rs4(C) 
1B 2 
rsl7(C) 
1B 3 
Ancestral 1B 6 
n18(G) IB4 
rs8(C), rs9(C), rslO(G) and 3762`(A) 
1B 5 
W(G) and n; 5(C) 
=1C_1 
rs10(G), rs11(A), rsl2(T), rs14(G), 4359 (C), 
rs2(G) rsl6(T), rs19(T) and 3762'(A) 1 C_2 
rs6(C) 
IA 
-1 
1A 2 
7837"(C), rs4(C), rs8(G), rs7(A), 
rs8(C), rs9(C), rsIO(G), rs11(A) 4359"(C) 
and 3762 (A) IA-3 
Figure 5.12: The hypothetical evolutionary tree of CCL3L 1/CCL4L 1 
haplotypes. 
Note: rs2= rs2944, rs3 = rs17850251, rs4 = rs2277661, 
rs5 = rs1804185, rs6 = rs1828283, rs7 = rs2073462, 
rs8 = rs4796195, rs9 = rs4796194, rs10 = rs4796193, 
rs11 = rs3744594, rs12 = rs3744595, rs14 = rs3744597, 
rs16 = rs2277660, rs17 = rs56363716, rs18 = rs56064808 and 
rs19 = rs1810104. (all SNPs are in dbSNP129) 
4359* and 3762* are variant bases which are not included in 
dbSNP129. 
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Although the association between CCL3LI/CCL4LI haplotype and 
their copy number was not found, this study has shown that the 
CCL3L 1/CCL4L 1 cluster is a complex region, with variation thought to 
have occurred by recombination. There have been reports showing 
that the variation in copy number of CCL3L I might be involved in the 
role of macrophages, especially with respect to susceptibility to 
infection, such as HIV and HCV infection (Gonzalez et al. 2005; 
Grünhage et al. 2010). In addition, CCL5, which is a ligand that binds 
and activates the same CCR5 receptor as CCL3L1, has been shown to 
be involved and associated (its functional polymorphisms) with 
tuberculosis (Saukkonen et al. 2002; Skwor et at 2006; Chu et al. 
2007). Therefore, the association study between CCL3L 1/CCL4L I 
copy number and tuberculosis should be investigated. More details are 
provided in the next chapter. 
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Chapter 6: Association study 
(CCL3LI/CCL4LI copy number and Tuberculosis) 
6.1 Introduction 
Tuberculosis (TB) is one of the most important infectious diseases and 
is caused by Mycobacterium tuberculosis. Globally, in 2009 there were 
an estimated 9.4 million new TB cases, and 1.7 million people died of 
TB (about 0.4 million of these people were HIV positive) (World Health 
Organization 2010). 
Interestingly, only about 10% of infected persons develop TB disease 
(Bloom and Murray 1992; Vynnycky and Fine 2000). Therefore human 
genetic variation might have a contribution to this difference in 
outcome. Consequently, human genetic risk factors for TB 
susceptibility have been interesting to study, to provide more 
understanding of aetiology of the disease which might be useful in 
personalized therapy and vaccination strategies (Muller et al. 2010). 
One of the most interesting candidate genes is CCL5, also known as 
RANTES (regulated on activation, normal T cell expressed and 
secreted). It can inhibit intracellular growth of M. tuberculosis and plays 
an important role as a protective immune response against M. 
tuberculosis infection (Saukkonen et al. 2002; Skwor et a!. 2006). 
Moreover, RANTES functional polymorphisms also have an 
association with TB susceptibility (Chu at al. 2007). 
133 
CCR5 is one of the receptors of CCL5, and also can be activated by 
other ligands, one of which is CCL3L1 (more details are described in 
1.4.4.2). 
As CCL3LI shares the receptor with CCL5 and is the most potent 
ligand for CCR5 to suppress HIV entry in HIV infection, CCL3L1 might 
also have a role in TB susceptibility. To test this hypothesis, therefore, 
an association study between CCL3L I copy number and TB was 
carried out by typing copy number and using the criteria to sieve the 
samples for association analysis as described in Walker (2009), with 
some modifications. 
The investigation of association between CCL3L 9/CCL4L I copy 
numbers and TB was performed in 219 TB patients and 158 controls in 
African population (i. e. ! Xhosa) using a triplex PRT assay to type for 
CCL3LI/CCL4LI copy number. However, due to the quality of DNA 
and the limited DNA quantity, only 170 cases and 129 controls were 
successfully typed using 2/3 systems in majority of samples. 
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Based on the data from the triplex PRT assay, the numbers of cases 
and controls could be divided into two groups according to the 
agreement of the triplex PRT assay components as shown in Table 
6.1. 
Table 6.1: Numbers of cases and controls divided by agreement of 
triplex PRT assay. 
Category Description Number Number of 
of cases controls 
A Any sample where the integer 112 79 
copy number is in unanimous 
agreement from all 3 
measurements 
B Any sample with 2 42 29 
measurements in agreement 
and 1 failed measurement 
Any sample where 3 measures 16 21 
are in agreement with each other 
and the overall average, and the 
third value is within 0.75 of that 
integer 
Total of useful results 170 129 
Total of unusable results 49 29 
Total 219 158 
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6.2 Results 
According to the data from Table 6.1, to reach a reliable result of the 
investigation of association between CCL3L 1/CCL4L 1 copy number 
and TB, the association was examined using two data sets. In the first, 
association was investigated using total numbers of cases and controls 
typed, which were 170 and 129, respectively. In the other, the 
association was analysed using only those cases and controls which 
showed complete agreement of triplex PRT assay, totally 112 cases 
and 79 controls. 
All results for both analyses, such as mean and standard deviation of 
normalised copy number in each system of triplex PRT of cases and 
controls, distribution of copy number value in cases and distribution of 
integer copy numbers were compared between cases and controls, 
and are shown in Tables 6.2 to Table 6.5 and Figures 6.1 to Figure 6.4. 
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Table 6.2: Mean and standard deviation of normalised copy number values 
for 170 Tuberculosis samples (all TB cases). 
CCL3C CCL4A LTR61 A Average 
Mean 3.15 3.18 3.64 3.33 
Standard deviation 1.41 1.32 1.55 1.35 
Table 6.3: Mean and standard deviation of normalised copy number values 
for 129 control samples (all control samples). 
CCL3C CCL4A LTR61A Average 
Mean 3.67 3.71 4.12 3.83 
Standard deviation 1.40 1.32 1.69 7ý "l 
Table 6.4: Mean and standard deviation of normalised copy number values 
for 112 selected Tuberculosis samples (complete agreement of triplex PRT 
assay TB cases). 
CCL3C CCL4A LTR61A Average 
Mean 2.97 3.03 3.24 3.08 
Standard deviation 1.28 1.26 1.29 1.25 
Table 6.5: Mean and standard deviation of normalised copy number values 
for 79 control samples (complete agreement of triplex PRT assay control 
samples). 
CCL3C CCL4A LTR61A Average 
Mean 3.46 3.49 3.71 3.55 
Standard deviation 1.35 1.29 1.31 1.30 
137 
Figure 6.1: Distribution of copy number values for 170 Tuberculosis 
samples (all TB cases). 
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8 
86 
4 
2 
0 
Figure 6.2: Distribution of copy number values for 112 selected 
Tuberculosis samples (complete agreement of triplex PRT assay TB 
cases). 
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Figure 6.3: Distribution of integer copy numbers for 170 Tuberculosis 
patients and 129 controls (all samples). 
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Figure 6.4: Distribution of integer copy numbers for 112 Tuberculosis 
patients and 79 controls (complete agreement of triplex PRT assay 
samples). 
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Integer Copy Number 
Two two-tailed T-tests were applied to investigate the association 
between CCL3LI/CCL4LI copy number and tuberculosis disease in 
both analyses. The results showed that lower CCL3L 9/CCL4L I copy 
number had a significant association with TB (p = 0.001 and 0.013, 
respectively). 
Furthermore, two x2 tests were used to examine for failure rate of 
CCL3LI/CCL4L1 copy number typing between cases and controls, and 
for frequency of complete agreement in triplex PRT assay among 
accepted samples. Both tests showed that there are no significant 
difference between cases and controls (p = 0.4395 and 0.6970, 
respectively). 
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Chapter 7: Discussion 
Studying the evolutionary history of variation at the CCL3L 1/ CCL4L I 
cluster might have an advantage for understanding the functions of the 
genes and the genetic basis of susceptibility or resistance to disease in 
which these genes play a role. The main objective of this study was to 
define the relationship between copy number variation of CCL3L I and 
SNPs flanking the CCL3LI/CCL4LI cluster and provided information 
on the evolution of haplotypes at CCL3LI/CCL4LI. 
7.1 CCL3L 1 pseudogene assay 
The CCL3L 1 pseudogene or CCL3L2 is a 5' truncated copy of 
CCL3L1; it has sequences similar to the CCL3L1 gene, but is lacking 
exon 1 of CCL3L1. Interestingly, the CCL3L1 pseudogene is found in 
humans but not in chimpanzee (Gornalusse et al. 2009), implying that 
the CCL3L1 pseudogene has just occurred in a single evolutionary 
lineage. 
Similar to CCL3LI/CCL4LI copy number, this study demonstrated that 
the CCL3L 1 pseudogene varies between individuals and in populations 
as the results showed that it is not present in every person and its 
frequency is found to significantly differ between populations 
(P = 0.001). Extrapolating from this result, the copy number 
measurement of CCL3L1 should be carried out carefully because the 
presence of this pseudogene might contribute to the measurement 
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error of some assays due to its sequence similarity to CCL3LI. For 
example, the CCL3LI pseudogene may account for the differences in 
copy number between CCL3L I and CCL4L I in the study of Townson 
et al. (2002). 
The association between copy number variants (CNVs) and 
pseudogenes has been characterised and it has been reported that 
there was an association between them (Kim et al. 2008). Although in 
this study CCL3L 1 pseudogene and CCL3L 1/CCL4L 1 copy number 
and haplotype of CCL3LI/CCL4LI copy number did not show a 
significant association in most populations, the results in this study 
showed a trend to support Kim's study for the following reasons; the 
mean copy number in CCL3L1 pseudogene containing group is higher 
than in the group for which the CCL3LI pseudogene is absent in all 
populations of study. Moreover, a higher frequency of presence of the 
CCL3LI pseudogene is found in the population with the highest copy 
number of CCL3LI/CCL4L1 (i. e. the rank of decreasing of CCL3LI 
pseudogene is found in Yoruba, CHB/JPT and UK and CEPH-HapMap, 
respectively). 
Recently, Shostakovich-Koretskaya et al. (2009) claimed that they 
found novel 5' exons for this pseudogene using bioinformatics and 
mRNA profiling, which could mean it has two alternatively spliced 
transcripts, and is predicted to be a functional gene rather than a 
pseudogene. This has led to a controversial issue of how to count the 
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CCL3LI copy number because the difference in method for quantifying 
CCL3L1 copy number could affect an investigation of association 
between CCL3L1 and diseases in which this gene might be involved 
(Shrestha et al. 2009). This is not a unique situation. Two variable 
pseudogenes (NCF1B and NCF1C) of neutrophil cytosolic factor-1 
(NCFI), which is a component of NADPH oxidase, also have been 
found to have alternative spliced expression and the variation of these 
pseudogenes may be biologically relevant (Brunson et al. 2010). 
Moreover, it has been estimated that about 20% of pseudogenes could 
be transcribed (Zheng et al. 2007). 
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7.2 SNPs and Microsatellites 
7.2.1 SNPs 
This study used 15 SNPs, which lie in both the flanking region and the 
copy-variable region of CCL3L1/CCL4LI, to test for an association of a 
SNP with CCL3L1/CCL4LI copy number. Whilst there is no perfect 
SNP which can be used to determine CCL3LI/CCL4LI copy number, 
the results suggested a combination of SNP rs8064426 and SNP 
rs16972085 can be used to predict the copy number of 
CCL3LI/CCL4LI in UK and Basque populations with about 70% 
accuracy. Neither of these SNPs, rs8064426 and 16972085, have 
been reported to be associated with a disease in the NHGRI GWAS 
catalogue (www. genome. gov/gwastudies). However, it is interesting 
that SNP rs16972085 is a rare variant in European and Asian 
populations, but not in African populations. This is also found in SNP 
rs1804185, which was selected from UCSC genome browser. The 
SNP did not show any variation in all ECACC samples tested. 
SNP rs4796195, a SNP which was analysed in this study, has been 
reported to have an association with the copy number of CCL4L1 
(Colobran et al. 2008). Surprisingly, the investigation of relationship 
between this SNP and the copy number of CCL3L1/CCL4LI in this 
study did not find any correlation. 
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Regarding the other studied SNPs, it seems that SNPs at the 
CCL3L1/CCL4LI variable region, rs3744594 and rs2277661, have a 
tentative relationship with CCL3L1/CCL4LI copy number as the results 
showed that these SNPs were associated with CCL3L1/CCL4LI copy 
number in most populations studied (i. e. ECACC, CHB/JPT and YRI for 
SNP rs3744594 and ECACC, CEPH HapMap and CHB/JPT for SNP 
rs2277661). Although these two SNPs were not useful for prediction of 
CCL3LI/CCL4L1 copy number, they still can be exploited for 
confirmation that a sample possesses a CCL3L 1/CCL4L I copy number 
of zero. 
In addition, the suggested SNPs from LD analysis which were used in 
this study also show potential and support the concept of LD 
application. Most suggested SNPs, 6 out of 8, based on LD analysis 
showed significant association with CCL3LI/CCL4LI copy number 
except SNP rs9910447 and SNP rs12453313. 
For the study of the relationship between SNPs and the CCL3L1 
pseudogene, the study showed that there were some SNPs associated 
with the presence of the CCL3LI pseudogene, but there was no one 
SNP that had an absolute association, even SNP rs16972085 which 
was suggested from LD analysis to be associated with the 
pseudogene. Therefore, in order to find a tag-SNP to detect the 
presence of the CCL3LI pseudogene, further investigation is still 
needed. 
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7.2.2 Microsatellites 
The compound microsatellite (CCL3CT) which is composed of CT-rich 
microsatellite was applied in a similar manner to SNPs to investigate 
association with CCL3L 1/CCL4L I copy number and the CCL3L 1 
pseudogene in ECACC samples. This microsatellite is located within 
the CCL3 constant region (Chr. 17: 31447038-31447215) which is 
approximately 99kb from the CCL3L I/CCL4L I variable region. It was 
investigated to see whether CCL3 varied in copy number (Walker 
2009). In summary, Walker (2009) analysed 87 Yoruba samples and 
found that most samples produced two products (including 2 samples 
which produced unequal intensity of peaks). The exception was 8 
samples which produced a single product and 4 samples produced 
three distinct products. Based on this microsatellite analysis, Walker 
(2009) suspected that CCL3 in African population could vary in copy 
number not just CCL3L I/CCL4L I. In addition, Walker (2009) 
suspected that a child in the study might have a somatic mutation. 
Similar to the study of Walker (2009), the study in ECACC samples 
also found that most samples (180 out of 192 samples) produced two 
products with equal height peaks, and a homozygous sample for the 
same allele length can be found as well (8 out of 192 samples). 
Interestingly, there were 4 samples 2 of which produced three distinct 
products of different size and 2 samples produced four different sized 
products. It was confirmed that 2 samples were mixed samples by 
using other microsatellites (i. e. D18S51 and D21S11, which usually are 
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used for individual identification (Kimpton et al. 1996)), and 2 samples 
remained that have been proposed to have a somatic mutation at 
CCL3CT. Based on the prevalence of samples with somatic mutation in 
this study and on the study of Walker (2009), it may be suggested that 
the CCL3 microsatellite is a sensitive region for somatic mutation, but 
further investigation is required. However, it could be summarized that 
there is no variation of CCL3 copy number in European population. 
CCL3CT microsatellite was not found to have a relationship with the 
copy number of CCL3L I/CCL4L I, and the association with CCL3L I 
pseudogene was weak (p = 0.0277). This might suggest that the 
CCL3CT microsatellite has a high rate of mutation, the 
CCL3L I/CCL4L 9 CNV has a high rate of mutation, and/or there has 
been frequent recombination at the CCL3L I and CCL4L I region. 
Lastly, although the study showed that this microsatellite does not have 
a relationship with CCL3LI/CCL4LI copy number, again this 
microsatellite might be used as a marker for detection and/or 
confirmation of zero copy number of CCL3L1/CCL4L1. However, more 
investigation is still needed to confirm this benefit. 
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7.3 Tag-SNPs and Haplotype block analysis 
Haplotype-based association studies were continued after SNP and 
microsatellite association studies were not successful to find a tag-SNP 
or a haplotype block to use for determination of copy number at 
CCL3L 1/CCL4L 1. LD was also investigated in this study by analysing 
1,250 HapMap SNPs flanking the CCL3LI/CCL4LI region (about 3 
Mb). However, for haplotype-based association studies, it is not easy to 
obtain valid haplotype phase information and errors of inferred phase 
information could be frequent (Clark 2004). In this study, several 
methods such as sequencing, segregation analysis, allele-specific PCR 
and emulsion haplotype fusion PCR were applied to identify 
CCL3L7/CCL4LI sequence haplotypes, but the problem of phase 
uncertainty was also still found; there were some haplotypes that 
cannot be defined for their CCL3LI/CCL4LI copy number (i. e. 32 out 
of 124 haplotypes). 
Surprisingly, although haplotype-based association studies were used 
to identify a SNP which had an association with CCL3LI/CCL4LI copy 
number, the results showed that there were no SNPs with a strong 
association with CCL3LI/CCL4L9 haplotypes or even with a sub-group 
of copy number haplotypes (see Tables 5.7-5.8). For example, for "I C" 
CCL3L 1/CCL4L I copy number haplotype group, which was the lowest 
frequency haplotype group (about 5% of observed 1-copy number 
haplotypes; see Table 5.5), an absolute LD tag-SNP was still not found 
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in this group. In order to identify this "IC" CCL3L I/CCL4L I copy 
number haplotype, a combination of two tag-SNPs was needed. 
Moreover, a combination of SNPs (rs8064426 and rs16972085) which 
was used to predict the CCL3LI/CCL4LI copy number in the UK and 
Basque populations is not suggested as a candidate tag-SNP in this 
study. In fact, in this study the SNP rs8064426 was the best SNP 
associated with 1 copy number of CCL3L 1/CCL4L I (D' = 45.1, LOD = 
2.82 and rz = 0.126), but this association was reduced in testing of 
association with haplotypes (1-copy number haplotype; D' = 46.4, LOD 
= 1.66 and r2 = 0.08) and sub-group haplotypes (type 1A haplotype: D' 
= 9, LOD = 0.00 and f2 = 0.000; type 1B haplotype: D'= 48.1, LOD = 
0.89 and r2 = 0.039, and type 1C haplotype: D= 100, LOD = 0.18 and 
r2 = 0.005). 
Usually haplotype-based association studies are assumed to provide 
greater power than using single genetic markers, but in this study it 
seemed that haplotyped-based approaches were not more 
advantageous than using single genetic makers. There were some 
suggestions that this might be because of uncertainty in the haplotype 
inference, or, as well as increasing the degrees of freedom in the 
haplotype-based association study (Cordell and Clayton 2005). An 
example of this evidence has also been found in the study of 
Pinnaduwage and Briollais (2005) which showed that haplotype-based 
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analysis had no advantage over genotype-based (single locus) 
analysis in the association study of alcohol dependence. 
Taken together, and based on several approaches, including SNP, 
microsatellite and haplotype, this work did not show a strong 
association between single-copy marker and CCL3L 1/CCL4L 1 copy 
number; this may suggest that CCL3LI/CCL4LI is a complex region 
and one plausible hypothesis is that there is a high rate of 
recombination in this region (more discussion in section 7.4). 
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7.4 Evolution of haplotypes at CCL3LI/CCL4LI 
To generate CCL3LI/CCL4L1 haplotypes, three different major single- 
copy CCL3L I/CCL4L I haplotypes were found. There were classified 
as 1A, 1B and IC types according to their sequence similarity (see 
Table 5.5). Comparison of these sequence haplotypes with reference 
sequences on UCSC browser showed that, type IA and type 1B 
haplotypes can be identified as type 1A located at chrl7: 31,546,382- 
31,548,269 and chrl7: 31,562,581-31,564,393 for CCL3LI and 
CCL4L 1, respectively, and type 1B annotated as CCL3L3/CCL4L2 
located at chrl7: 31,647,956-31,649,843 and chrl7: 31,664,147- 
31,665,959, respectively. However, both "CCL3L3" and "CCL4L2" are 
still designated in this study as CCL3L 1 and CCL4L 1, respectively 
because in each pair, CCL3L and CCL4L had identical sequences in 
coding regions (Colobran et at 2010; Shrestha et al. 2010). 
Although CCL4LI shared 100% nucleotide identity with CCL4L2 in the 
coding region, a variant intron 2 acceptor splice site was found in 
CCL4L 1 and creates a variety of mRNA isoforms (Colobran et at 
2005). Thus, the variation in the copy number of CCL4L might have 
functional effects. To date, the functional difference between CCL4L 1 
and CCL4L2 is unknown, but it was suggested that the new splicing in 
CCL4L1 might reduce its activity (Colobran at al. 2010). In fact, 
Colobran et at (2005) found that in individuals with only CCL4LI, it 
was expressed at a lower level than if only CCL4L2 is present (12% vs 
52% compared to CCL4 transcripts); they also found that the CCL4LI 
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allele was at higher frequency in HIV infected individuals than controls. 
However, further investigation is still needed to identify the importance 
of variation in the forms of CCL4L. 
Interestingly, it seemed that the type 1C haplotype, which had the 
lowest observed frequency (5%), was mutated from the type 1B 
haplotype. Two missense mutations were found in this group. One was 
found at CCL3L1 where SNP rs17850251 changed leucine to proline, 
and the other one was found in CCL4L1 in which SNP rs3744595 
altered arginine to histidine. Although the effects of these changes are 
still unknown, it is possible that the substitution of these amino acids 
might influence the folding of protein, resulting in an altered functional 
effect of CCL3L1/CCL4LI (Paximadis et al. 2009). 
Moreover, 2-copy CCL3LI/CCL4L1 haplotypes were found to be 
duplicated from 1-copy CCL3L J/CCL4L I haplotypes, supporting the 
study of Modi (2004) that found internal duplication in these regions. 
Evidence of recombination between CCL3L 1 and CCL4L I was also 
found in 2-copy haplotypes. These recombinations might explain the 
difficulty in finding a tag-SNP or a haplotype block in this region. 
Similarly, Paximadis et al. (2009) characterized CCL3 and CCL3L 1 
genes in 43 South African African (SAA) mother-infant pairs from a 
mother-to-infant HIV-1 transmission study, and in 28 South African 
Caucasian (SAC) adult volunteers. They also found only 3 classes of 
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CCL3L1 haplotypes in their study, which were the same as shown in 
this study. However, it should be noted that there were two variant 
bases at the 3' end of CCL3LI in the type 1A haplotype found only in 
the study of Paximadis of al. (2009) and not in this study, and a few 
bases at 3' and 5' end of CCL3LI overlapped between both studies. In 
summary, they found type 1B in SAA population and type 1C and type 
1A in SAC population. Surprisingly, type I B, which was most common 
in the European population in this study, was found only in the SAA 
population and did not appear in the SAC population in Paximadis at al. 
(2009). In addition, they also reported that type 1C was found at higher 
frequency than type 1A in the SAC population, while in this study the 
frequency of type 1A was found at twice the frequency compared to 
type 1 C. 
To investigate the evolution of CCL3L 1/CCL4L I haplotypes, the human 
haplotypes of CCL3L1/CCL4LI were compared to CCL3L1/CCL4LI 
haplotypes in chimpanzee. Interestingly, the CCL3L1/CCL4LI 
haplotype in chimpanzee was found to be identical to type 1B (i. e. 
113_6 haplotype) which was found at a frequency of nearly 70% in this 
study. Taken together with the result of Paximadis et a!. (2009), which 
reported type 1B haplotype as the only haplotype found in the African 
population, it could be surmised that type lB was the ancestral state 
haplotype of CCL3LI/CCL4LI. Also type 1A represents an internal 
duplication of type 1 B, and type 1C was a (mutated) derivative of type 
1 B. Moreover, it could be implied that the type 1B haplotype had a 
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significant functional role, in that it was kept through the evolution of 
CCL3L I/CCL4L I haplotypes without major changes. 
It is also important to note that a variant at the 3' end of CCL3 can be 
found both in sequences of chimpanzee and orang-utan, in which they 
were similar to CCL3L I. However, when these sequences were 
aligned to CCL3L1, they showed a lot of base substitutions similar to 
CCL3. For example in the study of Paximadis et al. (2009), they also 
compared CCL3L1 sequences from their population study with the 
sequence of chimpanzee from NCBI browser (GenBank accession 
number : NW 001226927). This sequence should not be annotated 
CCL3L1 because there were a lot of base substitutions characteristic of 
CCL3, although this sequence of chimpanzee had a deletion (the same 
as CCL3L 9) at the 3' end. 
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7.5 Association study 
TB is an important infectious disease. Many studies have suggested 
that genetic factors play a role in TB susceptibility (reviewed in Möller, 
et a!. 2009). CCL5 is one of the candidate genes shown to have an 
association with TB susceptibility (Chu at a!. 2007). CCL3LI is one of 
chemokines that shares its receptor with CCL5 (i. e. CCR5), and it has 
associations with HIV infection (Gonzalez et a!. 2005; Nakajima et al. 
2007), Kawasaki disease (Burns at a!. 2005; Mamtani at a!. 2010) and 
chronic hepatitis C (Grünhage et a!. 2010). As a result, CCL3LI should 
be also an interesting candidate gene. Surprisingly, until now, there is 
no report on a study of the association between CCL3L1 and TB. 
Thus, this might be the first study to show lower CCL3L1/CCL4LI copy 
number has a significant association with TB (p = 0.013). Moreover, 
this study is one of many to show that CCL3L1 is a genetic risk factor 
for infection susceptibility. It is not the only association study that 
shows possession of CCL3LI copy number lower than their population 
average to be associated with TB. The other studies also show that the 
possession of CCL3L1 copy number lower than their population 
average is correlated with susceptibility to HIV (Gonzalez et al. 2005; 
Nakajima et al. 2007) and HCV infection (Grünhage et a/. 2010). 
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However, the numbers of cases and controls that were used in this 
study is still small. Ideally this association should be investigated and 
replicated in a large number of cases and population matched controls 
to confirm the significant association between CCL3LIICCL4LI copy 
number and TB. 
In addition to CCL3L 1/CCL4L 1, their non-copy number variable 
paralogues CCL3 and CCL4, which bind to receptor CCR5, have also 
been tested for association with TB. Although, studies showed that 
variation at CCL3 is not associated with TB (Flores-Villanueva et al. 
2005), variation at CCL4 is (p = 0.002) (Jamieson et al. 2004). 
Collectively, several ligands of CCR5 show an association with TB. 
Therefore, the study of functional polymorphisms of CCR5 should also 
be investigated further for its association with TB. 
Although this study provides a good preliminary result, it still has a 
point that could be improved to make it more accurate and reliable in a 
further study; that is the measurement accuracy for CCL3LI/CCL4L1 
copy number. 
The triplex PRT assay which was applied to measure CCL3LI/CCL4LI 
copy number in this study still remains a problem in agreement of 
integer copy number between systems in some case and control 
samples (Table 6.1). It seems that the triplex PRT can accurately 
measure low copy number of CCL3L 1/CCL4L I but still struggles to 
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measure a high copy number of CCL3LI/CCL4LI. This problem was 
also found in the study of measurement of CCL3L I/CCL4L I copy 
number in Pygmy samples (with relatively high copy number, 3-10 
copies (Walker 2009)), although the measurement of CCL3LI/CCL4LI 
in UK population (with relatively low copy number, 0-4 copies) provides 
a highly robust result (Walker 2009). Therefore, the development of a 
triplex PRT assay for typing CCL3L I/CCL4L I in high copy number 
samples such as more than 3 or 4 copies is required. Moreover, the 
issue of the quality and amount of DNA samples also should not be 
avoided because it could affect the estimation of copy number. Urban 
et al. (2009) have reported that difference of DNA amounts can cause 
the differential bias in copy number using the real-time PCR method, 
and DNA shearing can lead to systematic copy number overestimation 
using the PRT method. 
In summary, to understand the evolutionary history of variation at the 
CCL3L1/CCL4LI region, CEPH-HapMap samples have been 
characterised for the CCL3L1/CCL4L1 haplotypes and compared to the 
chimpanzee CCL3L1/CCL4LI sequence. This study shows that there 
are 3 major haplotypes of CCL3L 1/CCL4L I (type 1A, 1B and 1 C) in the 
European population (i. e. CEPH-HapMap samples). The major 1-copy 
CCL3L 1/CCL4L 1 haplotype (type 1 B, found at about 70% frequency) is 
the ancestral state, as inferred by comparison with chimpanzee. The 2- 
copy CCL3LI/CCL4LI haplotypes are duplicated from 1-copy 
CCL3L 1/CCL4L 1 haplotypes. Interestingly, evidence of recombination 
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is also found in 2-copy CCL3LIICCL4LI haplotypes. As a result, this 
may suggest that CCL3LI/CCL4LI is a complex region and one 
plausible hypothesis is that there is a high rate of recombination in this 
region. With this assumption and the evidence of recombination which 
was identified in this study, this might be an explanation why there is 
no strong association between single-copy markers (SNPs and 
microsatellites), CCL3LI/CCL4L1 haplotypes and CCL3LI/CCL4LI 
copy number. The study also shows the variation of the CCL3LI 
pseudogene in individuals and in populations (UK, CEPH-HapMap, 
CHB/JPT and YRI). Although this CCL3L1 pseudogene is not 
significantly associated with CCL3L 1/CCL4L 1 copy number, there is a 
positive correlation between its presence and copy number. Work is 
still needed on the function and possible expression of this 
pseudogene. This is because the CCL3L 1 pseudogene can affect 
counting the CCL3L1 copy number and subsequently affect 
interpretation of association studies of CCL3LI copy number and 
disease (Shostakovich-Koretskaya et at 2009). Moreover, a robust 
standard technique to determine copy number variation particularly in 
the high copy number range is still urgently needed, in particular, for 
CCL3LI/CCL4LI copy number. 
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Table 1: Prediction of CCL3LI/CCL4LI copy number in ECACC 
samples (panel 1) by using SNP rs16972085 and SNP rs8064426. 
Sample SNP 
rs16972085 
SNP 
rs8064426 
Predicted 
CN 
PRT- CN 
C0744 N/A* GG N/A* 2 
C0147 AA AG 1 2 
C0888 AA AG 1 1 
00909 AA GG 2 2 
C0938 AA GG 2 3 
00027 AA AG 1 1 
C0184 AA GG 2 2 
C0969 N/A* AA N/A* 2 
C0145 AA GG 2 2 
00096 AA AA 0 2 
C0007 AA GG 2 3 
C0029 AA GG 2 2 
00156 AA GG 2 2 
C0143 AG GG 3 2 
00917 AA GG 2 1 
00093 AG AG 2 3 
C0140 AA GG 2 2 
C0877 AA GG 2 4 
00185 AG AG 2 4 
00063 AA GG 2 2 
C0937 AA GG 2 4 
C0861 AA GG 2 2 
C0207 AA GG 2 2 
C0202 AA GG 2 2 
00068 AA GG 2 2 
C0884 AA GG 2 2 
C0961 AA GG 2 2 
C0195 AA GG 2 2 
C0187 AA GG 2 1 
C0725 AA GG 2 3 
C0960 AA GG 2 2 
C0748 AA GG 2 2 
C0208 AA GG 2 1 
00100 AG GG 3 3 
00090 AG GG 3 3 
C0870 AA GG 2 2 
C0188 AA GG 2 2 
C0786 AA GG 2 2 
00097 AA GG 2 2 
C0176 AA GG 2 2 
00858 AA AG 1 1 
C0864 AA GG 2 3 
C0735 AA GG 2 3 
00088 GG GG 4 4 
C0739 AG GG 3 3 
C0204 AA GG 2 2 
C0194 AA GG 2 1 
C0126 AA GG 2 1 
C0978 AA GG 2 3 
C0183 AA GG 2 2 
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Table 1: Prediction of CCL3L1/CCL4L1 copy number in ECACC 
samples (panel 1) by using SNP rs16972085 and SNP rs8064426 
(continued). 
Sample SNP 
rs16972085 
SNP 
rs8064426 
Predicted 
CN 
PRT- CN 
C0053 AA GG 2 2 
C0766 AA AG 1 2 
00034 AA AG 1 2 
C0856 AA GG 2 2 
00896 AA GG 2 1 
C0215 AA GG 2 2 
C0136 AA GG 2 2 
C0913 AA GG 2 2 
C1006 GG AG 4** 4 
C0863 AA AG 1 1 
00152 AA AG 1 1 
00150 AA GG 2 2 
00899 AA GG 2 2 
C0747 AA GG 2 2 
00095 AA GG 2 2 
00075 AA AG 1 1 
C0906 AA GG 2 2 
00901 AA GG 2 2 
C0107 AG AG 2 3 
C0855 AA GG 2 2 
C0157 AA GG 2 2 
C0182 AA GG 2 2 
C0857 AA GG 2 3 
C0939 AA GG 2 2 
C0898 AA GG 2 1 
C0189 AA GG 2 2 
C0722 AA GG 2 2 
C0908 AA GG 2 1 
C0907 AG GG 3 3 
00849 AA GG 2 2 
C0121 AG GG 3 3 
00045 AA GG 2 3 
00073 AA AG 1 1 
00940 AA AG 1 1 
00080 AA GG 2 1 
C0997 AA GG 2 2 
C0904 AA GG 2 2 
00066 AA GG 2 1 
00108 AA AG 1 2 
C0941 AG GG 3 3 
C0996 AA GG 2 1 
00210 AA GG 2 3 
C0878 AG GG 3 2 
C0953 AA GG 2 3 
00081 AA GG 2 2 
00036 AG GG 3 2 
Note: *N/A = no t available 
**The prediction is based on the allele of SNP rs16972085 
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Table 2: Prediction of CCL3LI/CCL4LI copy number in ECACC 
samples (panel 2) by using SNP rs16972085 and SNP rs8064426. 
Code SNP 
rs16972085 
SNP 
rs8064426 
Predicted 
CN 
PRT- CN 
C0871 AA GG 2 2 
C0098 AA GG 2 3 
C0880 AA GG 2 2 
00061 AA GG 2 2 
C0018 AA GG 2 3 
C0724 AA GG 2 2 
C0892 AA GG 2 2 
C0164 AG AG 2 2 
00008 AA GG 2 2 
C0897 AA GG 2 2 
C0006 AA GG 2 2 
C0124 AA GG 2 2 
C0106 AA GG 2 2 
C0755 AA GG 2 2 
C0848 AG GG 3 3 
C0723 AA GG 2 2 
C0958 AA GG 2 2 
c0186 AA AA 0 0 
00058 AA GG 2 3 
C0862 AA GG 2 3 
00990 AA GG 2 2 
00030 AG GG 3 3 
C0123 AG GG 3 3 
01011 AA GG 2 1 
00113 AA GG 2 2 
00015 AA GG 2 2 
C0178 AA AG 1 1 
C0728 AG GG 3 3 
00035 AA GG 2 2 
C0166 AA GG 2 2 
00968 AA GG 2 2 
00040 AA GG 2 2 
00001 AG AG 2 2 
C0882 AA GG 2 2 
00055 AA GG 2 2 
C0846 AA GG 2 3 
C0967 AA GG 2 2 
00016 AA GG 2 2 
C0167 AA GG 2 2 
00051 AG GG 3 3 
00085 AA GG 2 2 
C0203 AA GG 2 3 
00881 AG GG 3 3 
C0850 AA GG 2 2 
00060 AA AG 1 1 
00191 AA GG 2 3 
C0894 AA GG 2 2 
C0192 AA AG 2 
00065 
00040 
AA 
AA 
AG 
GG 2 
2 
2 
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Table 2: Prediction of CCL3LI/CCL4LI copy number in ECACC 
samples (panel 2) by using SNP rs16972085 and SNP rs8064426 
(continued). 
Code SNP 
rs16972085 
SNP 
rs8064426 
Predicted 
CN 
PRT- CN 
C0921 AA AG 1 1 
C0920 AA AG 1 2 
C0752 AA GG 2 2 
C0052 AA AG 1 0 
C0731 AG AG 2 2 
C0959 AA GG 2 2 
C0002 AA AG 1 1 
C0135 AA GG 2 2 
C0161 AA GG 2 2 
00038 AA GG 2 2 
00084 AG GG 3 2 
00091 AA AG 1 1 
C0977 AA AG 1 1 
C0047 AA GG 2 2 
C0886 AA GG 2 3 
C0139 AA GG 2 2 
C0201 AA GG 2 2 
C0956 N/A* GG N/A* 2 
C0902 AA GG 2 2 
C0168 AG GG 3 2 
C0854 AA AG 1 1 
C0137 AA GG 2 2 
C0149 AA GG 2 3 
C0874 AA AG 1 1 
C0738 AA GG 2 2 
00180 AG AG 2 2 
C0160 AG GG 3 3 
00009 AA GG 2 2 
C0172 AA AG 1 1 
00190 AA GG 2 3 
C0154 AA GG 2 2 
c1010 AG GG 3 2 
C0741 AA AG 1 1 
C1008 AA GG 2 2 
C0994 AA GG 2 2 
00109 AA GG 2 2 
00111 AA GG 2 2 
00022 AA AG 1 1 
C0868 AA GG 2 2 
C0851 AA GG 2 2 
C0891 AA AG 1 1 
C0883 AA AG 1 1 
C0197 AG GG 3 3 
C0196 AA GG 2 2 
C0893 AA GG 2 2 
C0159 AA GG 2 2 
Note: *N/A = not available 
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Table 3: Prediction of CCL3L1/CCL4LI copy number in Basque 
samples by using SNP rs16972085 and SNP rs8064426. 
Code SNP 
rs16972085 
SNP 
rs8064426 
Predicted 
CN 
PRT- CN 
GK1 AA GG 2 2 
G K2 AA AG 1 3 
GK3 AA GG 2 1 
GK4 AA GG 2 2 
GK5 AA GG 2 2 
GK6 AG AG 2 1 
GK7 AA GG 2 2 
GK8 AA GG 2 2 
GK9 AG GG 3 3 
GK10 AA GG 2 3 
GK11 AA AG 1 1 
GK12 AA GG 2 2 
BM1 AA AG 1 1 
BM2 AA GG 2 2 
BM3 AA GG 2 2 
BM4 AA GG 2 2 
BM5 AA GG 2 2 
BM6 AA AG 1 1 
BM7 AA GG 2 2 
BM8 AA GG 2 2 
BM9 AA GG 2 2 
ZK1 AA GG 2 N/A* 
ZK2 AA GG 2 2 
ZK3 AA GG 2 2 
ZK4 AA GG 2 2 
ZK5 AA AG 1 1 
ZK6 AA GG 2 3 
ZK7 AA AG 1 1 
ZK8 AA GG 2 3 
ZK9 AA GG 2 2 
ZK10 AA AG 1 1 
ZK11 AA AG 1 1 
ZK12 AG GG 3 2 
ZK13 AA AG 1 3 
ZK14 AA AG 1 1 
ZK15 AA GG 2 2 
ZK16 AA GG 2 2 
ZK17 AA AG 1 1 
ZK18 AA GG 2 2 
ZK19 AA GG 2 2 
ZK20 AA GG 2 2 
ZK21 AA GG 2 2 
DT1 AA GG 2 2 
DT2 AA GG 2 3 
DT3 AA AG 1 1 
DT4 AA GG 2 2 
DT5 AA GG 2 2 
DT6 AG GG 3 3 
DT7 AA GG 2 2 
DT8 AA GG 2 2 
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Table 3: Prediction of CCL3L1/CCL4L1 copy number in Basque 
samples by using SNP rs16972085 and SNP rs8064426 (continued). 
Code SNP 
rs16972085 
SNP 
rs8064426 
Predicted 
CN 
PRT- CN 
DT9 AA GG 2 2 
DT10 AA AG 1 2 
DT11 AA GG 2 N/A* 
DT12 AA AG 1 1 
DT13 AA GG 2 1 
DT14 AA AG 1 2 
DT15 AA GG 2 2 
DT16 AA GG 2 2 
DT17 AG GG 3 3 
DT18 AA GG 2 1 
TX I AG GG 3 2 
TX2 AA GG 2 2 
TX3 AA GG 2 2 
TX4 AA GG 2 2 
TX5 AA GG 2 2 
TX6 AA GG 2 2 
TX7 AA GG 2 2 
TX8 AA AG 1 N/A* 
TX9 AA GG 2 2 
TX10 AA GG 2 3 
TX11 AA GG 2 2 
TX12 AA GG 2 3 
BS1 AA AA 0 0 
BS2 AA GG 2 4 
BS3 AA GG 2 3 
BS4 AA GG 2 1 
BS5 AA GG 2 2 
BS6 AG GG 3 2 
Vii AA GG 2 2 
V12 AA AG 1 1 
V13 AA GG 2 0 
V14 AG GG 3 2 
V15 AA GG 2 2 
V16 AA GG 2 2 
MR1 AA GG 2 2 
MR2 AA GG 2 2 
MR3 AA AG 1 1 
MR4 AA GG 2 2 
MR5 AA GG 2 2 
MR6 AA GG 2 2 
MR7 AA 2 2 
MR8 AA 2 2 
MR9 AA 
L 
2 3 
MR10 AA G 2 2 
MR11 AA 2 2 
MR12 AA GG 2 3 
MR13 AA GG 2 2 
LK1 AA GG 2 1 
LK2 AA AG 1 1 
LK3 AA GG 2 1 
LK4 AA GG 2 2 
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Table 3: Prediction of CCL3LI/CCL4L1 copy number in Basque 
samples by using SNP rs16972085 and SNP rs8064426 (continued). 
Code SNP 
rs16972085 
SNP 
rs8064426 
Predicted 
CN 
PRT- CN 
LK5 AA GG 2 2 
LK6 AA GG 2 2 
LK7 AA AG 1 1 
LK8 AA GG 2 2 
LK9 AA GG 2 3 
LK10 AA GG 2 3 
LK11 AA GG 2 3 
LK12 AA GG 2 2 
LK13 AA GG 2 3 
LK14 AA GG 2 3 
LK15 AA GG 2 3 
LK16 AA AA 0 3 
LK17 AA GG 2 2 
LK18 AA GG 2 2 
LK19 AA GG 2 2 
LK20 AA GG 2 2 
LK21 AA GG 2 2 
LK22 AA AG 1 1 
CA1 AA AG 1 1 
CA2 AA GG 2 2 
CA3 AA GG 2 2 
CA4 AG GG 3 4 
CA5 AA GG 2 2 
CA6 AA AA 0 0 
CA7 AG GG 3 2 
CA8 AA AG 1 3 
CA9 AA GG 2 2 
CA10 AA GG 2 2 
CA11 AA GG 2 2 
CA12 AA AG 1 1 
CA13 AA GG 2 2 
CA14 AA GG 2 1 
CA15 AG GG 3 3 
CA16 AA GG 2 2 
CA17 AA AG 1 1 
CA18 AA GG 2 3 
CA19 AG GG 3 3 
CA20 AA AG 1 1 
CA21 AA AG 1 1 
CA22 AA GG 2 2 
CA23 AA GG 2 2 
CA24 AA GG 2 2 
AM 1 AA GG 2 2 
AM2 AA GG 2 2 
AM3 AA GG 2 3 
AM4 AA GG 2 3 
AM5 AA GG 2 3 
AM6 AA AG 1 0 
IZ1 
1Z2 
1Z3 
AA 
AA 
AA 
GG 
GG 
GG 
2 
2 
2 
2 
2 
3 
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Table 3: Prediction of CCL3LI/CCL4L1 copy number in Basque 
samples by using SNP rs16972085 and SNP rs8064426 (continued). 
Code SNP 
rs16972085 
SNP 
rs8064426 
Predicted 
CN 
PRT- CN 
IZ4 AA AG 1 1 
IZ5 AA GG 2 2 
IZ6 AA GG 2 3 
IZ7 AA GG 2 2 
IZ8 AA GG 2 2 
Note: `N/A = not available 
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